[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 1 of 84 Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® 
Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 
2018–2019 Formulations 
Phase IV, multi- center, open -label study to assess the safety and immunogenicity of Fluzone® 
Quadrivalent vaccine in children and adults, Flublok® Quadrivalent vaccine in adults, and 
Fluzone® High-Dose vaccine in older adults  
Clinical Study Protocol 
Health Authority File Number:  BB-IND #: 4518  
WHO Universal Trial Number (UTN):  U1111- 1211 -4864 
Study Code: GRC90  
Development Phase:  Phase  IV 
Sponsor:  [COMPANY_011] Pasteur Inc.  
Discovery Drive, Swiftwater, PA [ZIP_CODE] -0187, [LOCATION_003] 
Investigational Products : Fluzone® Quadrivalent, Influenza Vaccine ( 2018– 2019 formulation) 
Flublok® Quadrivalent , Influenza Vaccine (2018 –2019 formulation ) 
Fluzone® High- Dose, Influenza Vaccine ( 2018– 2019  formulation)  
Form/Route: Liquid/Intramuscular  
Indication For This Study: To evaluate the safety and immunogenicity of the 2018– 2019 
formulations of Fluzone Quadrivalent vaccine in children 6 months to 
< 9 years of age and adults 18  to < 65 years of age, Flublok 
Quadrivalent  vaccine in adults 18  to < 65 years of age, and Fluzone  
High -Dose vaccine in adults ≥  65 years of age , with all study vaccines 
given by [CONTACT_654750]:  Same as Sponsor  
Coordinating Investigator : 
 
[INVESTIGATOR_36113]: ; Fax:  
Sponsor’s Responsible Medical 
Officers: ,   
 
Sanof
i Pasteur Inc.  
Tel:   
Fax:   
 
Sanof
i Pasteur Inc.  
Tel:   
Fax:   
Pharmaco vigilance Global Safety 
Expert:  
[COMPANY_011] Pasteur Inc.  
Tel: ; Email:  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 1 of 85Study ID: [REMOVED]

[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 2 of 84 Clinical Trial Manager:   
  
[COMPANY_011] Pasteur Inc.  
Tel: ; Fax:  
Version and Date of the Protocol:  Version 1.[ADDRESS_878612] parties without written authorization from [COMPANY_011] Pasteur . This document may not be reproduced, stored in a 
retrieval system, or transmitted in any form or by [CONTACT_61076] –electronic, mechanical recording, or otherwise –without prior 
authorization from [COMPANY_011] Pasteur . This document must be returned to [COMPANY_011] Pasteur  upon request.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 2 of 85

[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878613] version of the protocol.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 3 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878614] ..................................................................... 27  
1.3 Potential Benefits and Risks ........................................................................................... 29  
1.3.1 Potential Benefits to Subjects  ....................................................................................... 29  
1.3.2 Potential Risks to Subjects ........................................................................................... 29  
1.4 Rationale for the Study ................................................................................................... 31  
2 Study Objectives  .............................................................................................................. 31  
2.1 Observational Objectives  ................................................................................................ 31  
2.1.1 Safety  ............................................................................................................................ 31  
2.1.2 Immunogenicity ............................................................................................................ 31  
2.1.3 Serum Collection  .......................................................................................................... 32  
3 Investigators and Study Organization ........................................................................... 32  
4 Independent Ethics Committee/Institutional Review Board....................................... 32  
5 Investigational Plan  ......................................................................................................... 33  
5.1 Description of the Overall Study Design and Plan ......................................................... 33  
5.1.1 Study Design ................................................................................................................. 33  
5.1.2 Justification of the Study Design .................................................................................. 33  
5.1.3 Study Plan ..................................................................................................................... 33  
5.1.4 Visit Procedures  ............................................................................................................ 34  
5.1.5 Planned Study Calendar ................................................................................................ 38  
5.1.6 Early Safety Data Review  ............................................................................................. 39  
5.2 Enrollment and Retention of Study Population .............................................................. 39  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 4 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 5 of 84 5.2.1 Recruitment Procedures  ................................................................................................ 39  
5.2.2 Informed Consent Procedures ...................................................................................... 39  
5.2.3 Screening Criteria  ......................................................................................................... 40  
5.2.4 Inclusion Criteria  .......................................................................................................... 40  
5.2.5 Exclusion Criteria  ......................................................................................................... 40  
5.2.6 Medical History  ............................................................................................................ 42  
5.2.7 Contraindications for Subsequent Vaccinations ........................................................... 42  
[IP_ADDRESS] Temporary Contraindications ..................................................................................... 42  
[IP_ADDRESS] Definitive Contraindications  ...................................................................................... [ADDRESS_878615] 1 ........................................................................... 47  
[IP_ADDRESS] Composition  ............................................................................................................... 48  
[IP_ADDRESS] Preparation and Administration  ................................................................................. 48  
[IP_ADDRESS] Dose Selection and Timing ........................................................................................ [ADDRESS_878616] 2 ........................................................................... 48  
[IP_ADDRESS] Composition  ............................................................................................................... 49  
[IP_ADDRESS] Preparation and Administration  ................................................................................. 49  
[IP_ADDRESS] Dose Selection and Timing ........................................................................................ [ADDRESS_878617] 3 ........................................................................... 49  
[IP_ADDRESS] Composition  ............................................................................................................... 49  
[IP_ADDRESS] Preparation and Administration  ................................................................................. 49  
[IP_ADDRESS] Dose Selection and Timing ........................................................................................ [ADDRESS_878618] Shipment, Storage, and Accountability ........................................................... 50  
[IP_ADDRESS] Product Shipment ....................................................................................................... 50  
[IP_ADDRESS] Product Storage .......................................................................................................... 50  
[IP_ADDRESS] Product Accountability ............................................................................................... 51  
6.3.3 Replacement Doses  ....................................................................................................... 51  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 5 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 6 of 84 6.3.4 Disposal of Unused Products ........................................................................................ 51  
6.3.5 Recall of Products ......................................................................................................... 51  
6.4 Blinding and Code-breaking Procedures ........................................................................ 51  
6.5 Randomization and Allocation Procedures ..................................................................... 51  
6.6 Treatment Compliance  .................................................................................................... 52  
6.7 Concomitant Medications and Other Therapi[INVESTIGATOR_014]  ............................................................. 52  
7 Management of Samples ................................................................................................. 53  
7.1 Sample Collection  ........................................................................................................... 53  
7.2 Sample Preparation  ......................................................................................................... 54  
7.3 Sample Storage and Shipment ........................................................................................ 54  
7.4 Future Use of Stored Serum Samples for Research  ........................................................ 54  
8 Clinical Supplies  .............................................................................................................. 55  
9 Endpoints and Assessment Methods  ............................................................................. 55  
9.1 Primary Endpoints and Assessment Methods ................................................................. 55  
9.1.1 Safety  ............................................................................................................................ 55  
9.1.2 Immunogenicity ............................................................................................................ 55  
9.1.3 Efficacy  ......................................................................................................................... 55  
9.2 Secondary Endpoints and Assessment Methods ............................................................. 56  
9.2.1 Safety  ............................................................................................................................ 56  
9.2.2 Immunogenicity ............................................................................................................ 56  
9.2.3 Efficacy  ......................................................................................................................... 56  
9.3 Observational Endpoints and Assessment Methods ....................................................... 56  
9.3.1 Safety  ............................................................................................................................ 56  
[IP_ADDRESS] Safety D efinitions  ....................................................................................................... 56  
[IP_ADDRESS] Safety Endpoints ........................................................................................................ 59  
[IP_ADDRESS] Safety Assessment Methods ....................................................................................... 59  
[IP_ADDRESS].[ADDRESS_878619] -vaccination Observation Period ..................................................... 59  
[IP_ADDRESS].2 Reactogenicity (Solicited Reactions From Day  0 Through Day 7 After Each 
Vaccination)  ............................................................................................................. 60  
[IP_ADDRESS].3 Unsolicited Adverse Events  ..................................................................................... 68  
[IP_ADDRESS].[ADDRESS_878620]  .......................................................................... 69  
[IP_ADDRESS].5 Assessment of Causality  .......................................................................................... 70  
9.3.2 Immunogenicity ............................................................................................................ 70  
[IP_ADDRESS] Immunogenicity Endpoints ........................................................................................ 70  
[IP_ADDRESS] Immunogenicity Assessment Methods ....................................................................... 71  
9.3.3 Efficacy  ......................................................................................................................... 71  
9.3.4 Serum Collection  .......................................................................................................... 71  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 6 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 7 of 84 [IP_ADDRESS] Serum Collection Endpoints and Assessment Methods ............................................. [ADDRESS_878621] Has Completed the Study ...................... 73  
10.4 A ssessment of Causality  ................................................................................................. 73  
10.5 Reporting SAEs to Health Authorities and IECs/IRBs ................................................... 73  
11 Data Collection and Management ................................................................................. 73  
11.1 Data Collection and CRB Completion ............................................................................ 73  
11.2 Data Management  ........................................................................................................... 74  
11.3 Data Review  .................................................................................................................... 75  
12 Statistical Methods and Determination of Sample Size  ............................................... 75  
12.1 Statistical Methods  .......................................................................................................... 75  
12.1.1 Hypotheses and Statistical Methods for Primary Objectives  ....................................... 75  
12.1.2 Hypotheses and Statistical Methods for Secondary Objectives  ................................... 75  
12.1.3 Statistical Methods for Observational Objectives ........................................................ 75  
[IP_ADDRESS] Safety  .......................................................................................................................... 76  
[IP_ADDRESS] Immunogenicity ......................................................................................................... 76  
12.2 Analysis Sets ................................................................................................................... 76  
12.2.1 Safety Analysis Set  ....................................................................................................... 76  
12.2.2 Full Analysis Set ........................................................................................................... 76  
12.2.3 Per-Protocol Analysis Set ............................................................................................. 77  
12.2.4 Populations Used in Analyses ...................................................................................... 77  
12.3 Handling of Missing Data and Outliers .......................................................................... 77  
12.3.1 Safety  ............................................................................................................................ 77  
12.3.2 Immunogenicity ............................................................................................................ 77  
12.4 Interim/Preliminary Analysis  .......................................................................................... 78  
12.5 Determination of Sample Size and Power Calculation  ................................................... 78  
13 Ethical and Legal Issues and Investigator/Sponsor Responsibilities  .......................... [ADDRESS_878622] of the Study/Good Clinical Practice  ..................................................... [ADDRESS_878623] Records ................................................. 79  
13.4 Monitoring, Auditing, and Archiving ............................................................................. 79  
13.4.1 Monitoring .................................................................................................................... 79  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 7 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878624]  .................................................................................................................. 82  
15 Signature [CONTACT_3490]  ................................................................................................................. 84  
 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 8 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878625] of Tables  
Table 9.1: Solicited Injection Site Reactions: Terminology, Definitions, and Intensity Scales 
(Subjects 6 to < 36 Months of Age) ............................................................................................... 61  
Table 9.2: Solicited Injection Site Reactions: Terminology, Definitions, and Intensity Scales (Subjects 3 to < 9 Years of Age) .................................................................................................... 62
 
Table 9.3: Solicited Injection Site Reactions: Terminology, Definitions, and Intensity Scales (Subjects 18 Years of Age and Older) ............................................................................................ 63
 
Table 9.4: Solicited Systemic Reactions: Terminology, Definitions, and Intensity Scales (Subjects  6 to < 36 Months of Age) ............................................................................................... 65
 
Table 9.5: Solicited Systemic Reactions: Terminology, Definitions, and Intensity Scales (Subjects  3 to < 9 Years of Age and 18 Years of Age  and Older) ................................................ 66
 
 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 9 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 10 of 84 Synopsis 
Company:  [COMPANY_011] Pasteur  
Investigational Product s: Fluzone® Quadrivalent , Flublok® Quadrivalent,  and Fluzone® High -Dose 
Influenza Vaccines  (2018– 2019 Formulation s) 
Active Substances:  For Fluzone Quadrivalent and Flublok Quadrivalent vaccines , influenza 
virus surface antigens and recombinant hemagglutinin antigen, respectively, 
of the following strains:  
• A/Michigan/45/2015 (H1N1)  
• A/Singapore/INFIMH -16-0019/2016 (H3N2)  
• B/Maryland/15/2016 (B Victoria lineage)  
(a B/Colorado/06/2017- like virus)  
• B/Phuket/3073/2013 (B Yamagata lineage) 
For Fluzone High- Dose , influenza virus surface antigen s of the following 
strains:  
• A/Michigan/45/2015 (H1N1)  
• A/Singapore/INFIMH -16-0019/2016 (H3N2)  
• B/Maryland/15/2016 (B Victoria lineage)  
(a B/Colorado/06/2017 -like virus ) 
  Title of the Trial:  Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® 
Quadrivalent, and Fluzone® High -Dose, Influenza Vaccines, 2018 –2019 
Formulations  
Development Phase: Phase IV  
Coordinating Investigator: 
 
[INVESTIGATOR_654733] : This will be a multi -center study conducted in 3 sites in the [LOCATION_002].  
Investigators and sites are listed in the “List of Investigators and Centers 
Involved in the Trial” document.  
Planned Study  Period: First Visit, First Subject: September [ADDRESS_878626]: December 2018  
Study Design, Schedule of Study 
Procedures , and Methodology:  This will be a Phase IV, multi -center, open -label study of a planned 
240 subjects to describe the safety and immunogenicity of Fluzone 
Quadrivalent vaccine in children 6 months to < 9 years of age and adults 
18 to < 65 years of age, Flublok Quadrivalent vaccine in adults 18 to < 65 
years of age , and Fluzone High -Dose vaccine in adults ≥  65 years of age. 
Using a pre -programmed interactive response technology (IRT) system, 
each subject will be assigned to a vaccine group based on the subject’s age at the time of enrollment. An approximately equal number of subjects from 
each group will be enrolled at each site.  
Using the IRT system, subjects 18 to < 65 years of age will be randomly assigned to either Group 3 or Group 4. Enrollment in Group 3 and Group 4 will be stratified by [CONTACT_42889] 2 subgroups at  each site so that approximately 
50% of subjects at each site will be 18  to < 50 years of age and 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 10 of 85

[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 11 of 84 approximately 50% of subjects at each site will be 50 to <  65 years of age , 
and so that an equal proportion of subjects within each age subgroup receive 
eithe r Fluzone Quadrivalent or Flublok Quadrivalent vaccine. If necessary to 
achieve 50% overall enrollment of subjects 50  to < 65 years of age and 
assignment of Fluzone Quadrivalent and Flublok Quadrivalent vaccines in a 
1:1 ratio within each age subgroup (i.e ., 18 to < 50 years of age and 50 to 
< 65 years of age), individual sites may be permitted to deviate from these 
ratios.  
• Group 1: Children 6 to < 36 months of age assigned to receive a 0.25-mL dose of Fluzone Quadrivalent vaccine (30 subjects planned)  
• Grou p 2: Children 3 to < 9 years of age assigned to receive a 0.5 -mL 
dose of Fluzone Quadrivalent vaccine (30 subjects planned)  
• Group 3: Adults 18
 to < 65 years of age assigned to receive a 0.5 -mL 
dose of Fluzone Quadrivalent vaccine (60 subjects planned)  
• Group 4: Adults 18 to < 65 years of age assigned to receive a 0.5 -mL 
dose of Flublok Quadrivalent vaccine (60 subjects planned)  
• Group 5: Adults ≥ 65 years of age assigned to receive a 0.5 -mL dose of 
Fluzone High- Dose vaccine (60  subjects planned)  
 
Vaccination  
All subjects will receive either a 0.25 -mL (subjects 6 to < 36 months of age 
[Group 1]) or a 0.5 -mL (subjects 3 to < 9 years of age and ≥ 18 years of age 
[Groups 2, 3, 4, and 5]) intramuscular injection of study vaccine based on 
their assigned group at Visit 1. For subjects 6 months to < 9 years of age for whom 2 doses of influenza vaccine are recommended per Advisory 
Committee on Immunization Practices  guidance, a  second intramuscular  
injection of Fluzone Quadrivalent vaccine (same 0.25 -mL or 0 .5-mL volume 
as administered at Visit  1) will be administered at Visit 2 (28  [window, 28 –
35] days after Visit 1).  
Blood Sampling Collection of Safety Data  
Study sites, at their discretion, may apply a topi[INVESTIGATOR_654734]. However, topi[INVESTIGATOR_654735].  
Subjects 6 months to < 9 Years of Age  (Group 1 and Group 2):  
Blood specimens (approximately 5 mL) will be obtained from all subjects 
prior to the first vaccination at Visit 1 (Day 0) and 28 (window, 28 –35) days 
following the final vaccination (Visit 2, if no study vaccine is administered at Visit 2; or Visit 3, if a second dose of study vaccine is administered at Visit  2) and assayed for immunogenicity .  
Staff will observe subjects for [ADDRESS_878627] the occurrence of any immediate unsolicited 
systemic adverse events (AEs). Subjects’ parents/guardians will record 
information about solicited injection si te and systemic reactions from Day [ADDRESS_878628] information about 
unsolicited non -serious AEs and serious adverse events (SAEs) from Visit  [ADDRESS_878629] parents/guardians by [CONTACT_45347] 8 
(window,  Days  8–10) after any study vaccine administration to remind them 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 11 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878630] with them to the next visit. Parents/guardians will also be reminded to 
notify the site immediately if an SAE occurs.  
Staff will review the Visit 1  through Visit 2 safety data for all vaccinated 
subjects with parents/guardians at Visit 2. Staff will also review the Visit 2 
through Visit 3 safety data with parents/guardians at Visit 3 for subjects 
receiving 2 doses of study vaccine.  
Subjects ≥ 18 year s of age  (Group 3, Group 4, and Group 5):  
Blood specimens (approximately 2 0 mL) will be obtained from all subjects 
prior to vaccination at Visit 1  and 21 (window, 21 –28) days post- vaccination 
(Visit 2).  
Staff will observe subjects for [ADDRESS_878631] subjects by [CONTACT_45347] 8 (window, Days 8 –10) after 
study vaccine administration to remind them to record any AEs experienced and any concomitant medications taken from the most recent visit to the 
next visit in the diary card and to bring the diary card with them to the next 
visit. Subjects will also be reminded to notify the site immediately if an SAE occurs.  
Staff will review the Visit 1 through Visit 2 safety data for all vaccinated 
subjects at Visit  2.
  
Early Safety Data Review:  This study will not include an early review of safety data. However, it may 
be interrupted at any time if new data about the investigational products become available, and/or on advice of the Sponsor, the Institutional Review 
Board(s) (IRB[s]), or the Food  and Drug Administration (FDA).  
Interruption of the Study:  The study may be discontinued if new data about the investigational product(s) resulting from this study or any other studies become available; 
or for administrative reasons; or on advice of the Sponsor, the Investigators, 
the IRB(s), or the governing regulatory authorities in the country where the 
study is taking place.  
If the study is prematurely terminated or suspended, the Sponsor shall 
promptly inform the Investigators, the IRB(s), the regul atory authorities, and 
any contract research organization(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_56859]. The Investigator shall promptly inform the study subjects or 
subjects’ paren ts/guardians, as appropriate , and should assure appropriate 
subject therapy and/or follow- up.
 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 12 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 13 of 84 Observational Objectives:  Safety  
To describe the safety of the 2018 –2019 formulation of Fluzone 
Quadrivalent vaccine in children 6 to < 36 months of age and 3 t o < 9 years 
of age, and in adults 18 to < 65 years of age, the safety of the 2018 –2019 
formulation of Flublok Quadrivalent vaccine in adults 18 to < 65 years of 
age, and the safety of the 2018– 2019 formulation of Fluzone High -Dose 
vaccine in adults ≥ 65 ye ars of age.  
Immunogenicity  
To describe the immunogenicity of the 2018– 2019 formulation of Fluzone 
Quadrivalent vaccine in children 6 to < 36 months of age and 3 to < 9 years of age, and in adults 18 to < 65 years of age, the immunogenicity of the 
2018 –2019 formulation of Flublok Quadrivalent vaccine in adults 18 to 
< 65 years of age, and the immunogenicity of the 2018 –2019 formulation of 
Fluzone High- Dose vaccine in adults ≥ 65 years of age.  
Serum Collection  
To provide  available sera (collected from subjects before vaccination [Blood 
Sample 1] and after final vaccination [Blood Sample 2]) to the Center for Biologics Evaluation and Research for further analysis by [CONTACT_38375], the Centers for Disease Control and Prevention, and t he FDA 
to support formulation recommendations for subsequent influenza vaccines.  
In addition, available sera from adult subjects may be further analyzed by 
[CONTACT_654751].  
Observational Endpoints: Safety  
1) Occurrence, nature (Medical Dictionary for Regulatory Activities 
[MedDRA] preferred term), duration, intensity, and relationship to 
vaccination of any unsolicited systemic AEs reported in the 20 minutes 
after vaccination.  
2) Occurrence, time to o nset, number of days of occurrence, intensity, 
action taken, and whether the reaction led to early termination from the study, of solicited injection site reactions (prelisted in the subject’s diary card and  case report book [CRB])  occurring from Day  0 through 
Day 7 after vaccination.  
3) Occurrence, time to onset, number of days of occurrence, intensity, action taken, and whether the reaction led to early termination from the 
study, of solicited systemic reactions (prelisted in the subject’s diary 
card and CRB) occurring from Day 0 through Day 7 after vaccination.  
4) Occurrence, nature (MedDRA preferred term), time to onset, duration, 
intensity, action taken, relationship to vaccination (for systemic AEs 
only), and whether the event led to early termination from t he study, of 
unsolicited AEs from Visit 1 through Visit  2 for subjects receiving 
1 dose or from Visit 1 through Visit 3 for subjects receiving 2 doses.  
5) Occurrence, nature (MedDRA preferred term), time to onset, 
seriousness criteria, relationship to vaccina tion, outcome, and whether 
the SAE led to early termination from the study, of SAEs from Visit [ADDRESS_878632] will be captur ed as SAEs. These include 
new onset of Guillain -Barré syndrome (GBS), encephalitis/myelitis 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 13 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 14 of 84 (including transverse myelitis), neuritis (including Bell’s palsy, optic 
neuritis, and brachial neuritis), thrombocytopenia, vasculitis, convulsions 
(including febr ile convulsions [children only]), and anaphylaxis or other 
hypersensitivity/allergic reactions from Visit 1 through Visit 2 for subjects 
receiving 1 dose of vaccine, or from Visit 1 through Visit 3 for subjects 
receiving 2 doses of vaccine.  
Immunogenicity  
Immunogenicity will be evaluated in all subjects by [CONTACT_654752] 0 (Visit  1) and after final vaccination 
(28 [window, 28 –35] days post- final vaccination for subjects 6 months to 
< 9 years of age [Visit 2 for subjects  receiving 1 dose; Visit 3 for subjects 
receiving 2 doses]; or 21 [window, 21– 28] days post- vaccination for 
subjects ≥ 18 years of age) using the hemagglutination inhibition (HAI) 
assay technique.  
For each influenza vaccine strain (i.e., 3  strains for Flu zone High -Dose 
vaccine [a trivalent vaccine] and 4 strains for Fluzone Quadrivalent vaccine and Flublok Quadrivalent vaccine), HAI assay titers at pre -vaccination 
(Day  0) and after the final vaccination will be determined in duplicate.  
The derived endpoints
a are: 
• Geometric means of HAI assay titers at pre -vaccination and post -final 
vaccination  
• Ratios of post -final vaccination titers divided by [CONTACT_094] -vaccination titers  
• Seroprotection: a titer ≥  40 (l/dilution [dil]) at pre -vaccination and at 
post-final vacci nation  
• Seroconversion: either a pre -vaccination titer < 10 (1/dil) and a post -
final vaccination titer ≥ 40 (1/dil), or a pre -vaccination titer ≥ 10 (1/dil) 
and a ≥ 4-fold increase in post -final vaccination titer  
a   Post- final vaccination in each of the derived endpoints is defined as 
 28 (window, 28 –35) days post- final vaccination for subjects 6 months to 
 < 9 years of age, and 21 (window, 21– 28) days post- vaccination for 
 subjects ≥ 18 years  of age 
Serum Collection  
There are no observational endpoints for the serum collection objective.  
Planned Sample Size:  The study will enroll approximately 240 subjects: approximately 30 subjects 6 to < 36 months of age will be administered Fluzone Quadrivalent vaccine 
(Group  1), approximately 30 subjects 3 to < 9 years of age will be 
administered Fluzone Quadrivalent vaccine (Group  2), approximately 
60 subjects 18 to < 65 years of age will be administered Fluzone 
Quadrivalent vaccine (Group 3), approximately 60 subjects 18 to < 65 years 
of age will be administer ed Flublok Quadrivalent vaccine (Group 4), and 
approximately 60  subjects ≥  65 years of age will be administered Fluzone 
High -Dose vaccine (Group 5).  
No study power assessment will be done for this study. Only descriptive statistical analyses will be conducted in this study.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 14 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 15 of 84 Duration of Participation in the 
Study: Subjects 6 months to < 9 years of age: 28 (window, 28– 35) days following 
the last dose of influenza vaccine, including immunogenicity and safety follow -up. No additional safety follow -up beyond Visit 2 (for subjects 
receiving 1  dose) or Visit 3 (for subjects receiving 2 doses) is planned.  
Subjects ≥ 18 years of age: 21 (window, 21– 28) days after vaccination, 
including immunogenicity and safety follow -up. No additional safety 
follow -up beyond Visit [ADDRESS_878633] 1:  Fluzone Quadrivalent vaccine, No Preservative: Pediatric Dose (0.25 -mL 
dose), 2018 –2019 formulation  
or 
Fluzone Quadrivalent vaccine, No Preservative (0.5 -mL dose), 2018 –2019 
formulation  
 Form:  Liquid – pre-filled syringes  
 Composition:  Each 0.25 -mL dose contains 7.5 µg hemagglutinin (HA) of each antigen, 
and each 0.5 -mL dose contains 15 µg HA of each antigen:  
• A/Michigan/45/2015 (H1N1)  
• A/Singapore/INFIMH -16-0019/2016 (H3N2)  
• B/Maryland/15/2016 (B Victoria lineage)   
(a B/Colorado/06/2017- like virus)  
• B/Phuket/3073/2013  (B Yamagata lineage)   
 Route:  Intramuscular  
 Batch Number:  TBD  
Licensed Study Product 2 : Flublok Quadrivalent vaccine, 2018 –2019 formulation  
 Form:  Liquid – pre-filled syringes  
 Composition:  Each 0.5-mL dose contains 45 µg recombinant HA of each antigen:  
• A/Michigan/45/2015 (H1N1)  
• A/Singapore/INFIMH -16-0019/2016 (H3N2)  
• B/Maryland/15/2016 (B Victoria lineage)  
(a B/Colorado/06/2017- like virus)  
• B/Phuket/3073/2013 (B Yamagata lineage)   
 Route:  Intramu scular  
 Batch Number:  TBD  
Licensed Study Product 3:  Fluzone High- Dose vaccine, 2018 –2019 formulation 
 Form:  Liquid – pre-filled syringes  
 Composition:  Each 0.5 -mL dose contains 60 µg HA of each antigen:  
• A/Michigan/45/2015 (H1N1)  
• A/Singapore/INFIMH -16-0019/2016 (H3N2)  
• B/Maryland/15/2016 (B Victoria lineage)  
(a B/Colorado/06/2017 -like virus)  
 Route:  Intramuscular  
 Batch Number:  TBD  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 15 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 16 of 84 Inclusion Criteria:  An individual must fulfill all of the following criteria to be eligible for study 
enrollment: 
1) Aged 6 months to < 9 years or ≥ [ADDRESS_878634] study 
vaccination (study product administration).  
2) For subjects 6 to <  12 months of age, born at full term of pregnancy 
(≥ 37 weeks) and with a birth weight ≥  2.5 kg (5.5 lbs).  
3) Informed consent form (ICF) has been signed and dated by [CONTACT_1766] 
≥ 18 years of age.  
4) Assent form has been signed and dated by [CONTACT_1766] 7 to < 9 years of 
age, and ICF has been signed and dated by [CONTACT_7078](s) or guardian(s) for 
subjects 6 months to <  9 years of age.  
5) Subject and parent/guardian (of subjects 6 months to < 9 years of age) are able to attend all scheduled visits and to comply with all study 
procedures.  
Exclusion Criteria:  An individual fulfilling any of the following criteria is to be excluded from 
study enrollment:  
1) Subject is pregnant, or lactating, or of childbearing potential and not using an effective method of contraception or abstinence from at least 
[ADDRESS_878635] 1 year, or 
surgically sterile.  
2) Participation at the time of study enrollment (or in the [ADDRESS_878636]  study vaccination) or planned participation during 
the present study period in another clinical study investigating a 
vaccine, drug, medical device, or medical procedure.  
Note:  Subjects may be considered eligible for enrollment if no 
intervention for the  other study occurred within the [ADDRESS_878637] would 
complete safety surveillance for the present study.  
3) Receipt of any vaccine in the [ADDRESS_878638] study 
vaccination, or planned receipt of any vaccine before Visit 2 for 
subjects receiving 1  dose of influenza vaccine or Visit 3 for subjects 
receiving 2 doses of influenza vaccine.  
4) Previous vaccination against influenza (in the 2018 –2019 influenza 
season) with either study va ccine or another vaccine.  
5) Receipt of immune globulins, blood, or blood -derived products in the 
3 months preceding planned inclusion.  
6) Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti -cancer 
chemotherapy or radiation therapy, within the 6 months preceding 
planned inclusion; or long- term systemic corticosteroid therapy 
(prednisone or equivalent for more than 2 consecutive weeks within the 
3 months preceding planned inclusion).  
7) Known systemic hype rsensitivity to any of the vaccine components, or 
history of a life -threatening reaction to study vaccine or to a vaccine 
containing any of the same substances.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 16 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 17 of 84 Note:  The list of vaccine components is included in the Prescribing 
Information for each study  vaccine.  
8) Thrombocytopenia, which may be a contraindication for intramuscular 
vaccination, at the discretion of the Investigator.  
9) Bleeding disorder, or receipt of anticoagulants in the 3 weeks 
preceding inclusion, contraindicating intramuscular vaccination. 
10) Deprived of freedom by [CONTACT_29511], or in an 
emergency setting, or hospi[INVESTIGATOR_29476].  
11) Current alcohol abuse or drug addiction.  
12) Chronic illness that, in the opi[INVESTIGATOR_689], is at a stage where it might interfere with study conduct or completion.  
13) Moderate or severe acute illness/infection (according to Investigator judgment) on the day of planned vaccination or febrile illness (temperature ≥  100.4° F [38.0 °C]). A prospective subject should not be 
included in the study until the condition has resolved or the febrile event has subsided.  
14) Identified as an Investigator or employee of the Investigator or study 
center with direct involvement in the proposed study (subjects 
≥ 18 years of age) or identified as an immediate f amily member 
(i.e., parent, spouse, natural or adopted child) of the Investigator or 
employee with direct involvement in the proposed study (all subjects).  
15) History of serious adverse reaction to any influenza vaccine.  
16) Personal history of GBS.  
17) Any condition  that in the opi[INVESTIGATOR_35261] a 
health risk to the subject if enrolled or could interfere with the 
evaluation of the vaccine.  
18) Personal history of clinically significant developmental delay (at the 
discretion of the Investigator), neur ologic disorder, or seizure disorder.  
19) Known seropositivity for human immunodeficiency virus, hepatitis B, or hepatitis C.  
Note: Subjects enrolled into this study will not be prohibited from donating 
blood for non -interventional studies or other purposes.  
Statistical Methods:  Summaries of baseline demographic characteristics of the study subjects will 
be presented. The number of subjects enrolled and their age at enrollment (mean, median, and minimum and maximum), sex, race, and ethnic origin will be summar ized, along with the number and description of protocol 
deviation s. 
For the main safety and immunogenicity parameters, 95% confidence intervals (CIs) of point estimates of proportions will be calculated using the normal approximation for quantitative data and the exact binomial distribution (Clopper -Pearson method) for proportions. All analyses will be 
descriptive; no hypotheses will be tested.  
Safety  
The Safety Analysis Set will be used for the safety analyses. Subjects will be analyzed according to the vaccine they actually received.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 17 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 18 of 84 Immunogenicity  
The immunogenicity analyses will be performed on both the Full Analysis 
Set and the Per -Protocol Analysis Set. Data will be summarized and 
presented for each group.  
The following immunogenicity parametersa will be calculated for each 
influenza strain with 95% CIs: 
• Geometric mean HAI assay titers at pre -vaccination and post -final 
vaccination  
• Geometric means of titer ratios (post -final vaccination divided by [CONTACT_094] -
vaccination).  
• Seroprotection rates: The percen tages of subjects with a titer ≥ 40 (l/dil) 
at pre -vaccination and at post -final vaccination  
• Seroconversion rates: The percentages of subjects with either a pre -
vaccination titer < 10 (1/dil) and a post -final vaccination titer 
≥ 40 (1/dil), or a pre -vacci nation titer ≥ 10 (1/dil) and a ≥ 4-fold 
increase in post -final vaccination titer  
a  Post-final vaccination in each of the immunogenicity parameters is 
 defined as 28 (window, 28–35) days post -final vaccination for subjects 
 6 months to < 9 years of age, and 21 (window, 21 –28) days post -
 vaccination for subjects ≥ 18 years of age.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 18 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 19 of 84 Tables of Study Procedures  
Study Flow Chart for Subjects 6 Months to < 9 Years of Age: [ADDRESS_878639]  Visit 3 
Study Timelines  Day 0 Visit 1 + 8 days  Visit 1 + 28 days  Visit 1 + 28 days  Visit 2 + 8 days  Visit 2 + 28 days  
Time Windows  -- + 8 to 10 days  + 28 to 35 days  + 28 to 35 days  + 8 to 10 days  + 28 to 35 days  
Informed consent/assenta X      
Inclusion & Exclusion Criteria  X      
Demographic data  X      
Medical history  X      
Influenza vaccination history  X      
History -directed physical examination  X   X   
Temperatureb X   X   
Review contraindications for vaccination     X   
Allocation of subject number  X      
Blood sample (BL)c BL1  BL2   BL2 
Vaccinationd X   X   
Immediate surveillance (20 minutes)  X   X   
Diary card (DC) provided  DC1    DC2    
Telephone contacte  X   X  
Diary card reviewed and collected    DC1  DC1   DC2  
Interim history    X X  X 
Termination recordf    X   X 
Serious adverse events  To be reported throughout the study period  
a Informed consent form will be signed and dated by [CONTACT_7078](s) or guardian(s) for subjects 6 months to < 9 years of age and assent form will be signed and dated by [CONTACT_1766] 7 to < 9 years of age.  
b The preferred route for this study  is rectal for subjects 6 to < 36 months of age, and oral for subjects 3 to <  9 years of age. The axillary route may be used when a rectal or oral temperature cannot 
be obtained.  
c A blood sample, approximately 5 mL, will be collected from all subjects at Visit 1, prior to vaccination, and at either Visit  2 (for subjects receiving 1 influenza vaccine dose) or at Visit 3 (for 
subjects receiving 2 influenza vaccine doses).  
d One or [ADDRESS_878640] during the study. If 2 doses of influenza vaccine are 
indicated, 1 dose will be administered during Visit 1 and the second dose (same 0.25-mL or 0.5-mL volume of Fluzone Quadrivalent vaccine as administered at Visit  1) will be administered 
approximately [ADDRESS_878641]’s parent/guardian will be contact[CONTACT_304159] 8 (window, Days 8–10) after vaccination as a reminder to complete the diary card and to bring it with them to the next visit.  
f The termination form will be completed at Visit 2 for subjects receiving 1 dose of influenza vaccine or at Visit 3 for subjects receiving 2 doses of influenza vaccine . 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 19 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 20 of 84 Study Flow Chart for Subjects ≥ 18 Years of Age: [ADDRESS_878642]  Visit 2 
Study Timelines  Day 0 Visit 1 + 8 days  Visit 1 + 21 days  
Time Windows   + 8 to 10 days  + 21 to 28 days  
Informed consent  X   
Inclusion/exclusion criteria  X   
Demographic data  X   
Medical history  X   
Influenza vaccination history (previous season)  X   
History -directed physical examination  X   
Temperaturea X   
Urine or serum pregnancy testb X   
Allocation of subject number  X   
Blood sampling (BL)c  BL1  BL2 
Vaccination  X   
Immediate surveillance (20 minutes)  X   
Diary card provided X   
Telephone contactd  X  
Diary card reviewed and collected    X 
Termination record    X 
Serious adverse events  To be reported throughout the study period  
a The preferred route for this study  for subjects ≥ 18 years of age is oral.  
b Only for women of child -bearing potential.  
c A blood sample, approximately 2 0 mL, will be collected at Visit 1 and Visit 2.  
d Subjects will be contact[CONTACT_152087] 8 (window, Days 8 –10) as a reminder to complete the diary card 
and to bring it with them to Visit 2.  
 
 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 20 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878643] 
GBS  Guillain-Barré Syndrome 
GCI Global Clinical Immunology 
GCP  Good Clinical Practice  
GPE  Global Pharmacovigilance & Epi[INVESTIGATOR_654736]3 Trivalent Inactivated Influenza Vaccine  
IME Important Medical Event  
IND Investigational New Drug (Application)  
IRB Institutional Review Board  
IRT Interactive Response T echnology  
LLT Lowest Level Term  
LLOQ  Lower Limit of Quantification  
LVLS  Last Visit, Last S ubject  
MedDRA  Medical Dictionary for Regulatory Activities  
NA Neuraminidase  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 21 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878644] Dose Quadrivalent Inactivated Influenza Vaccine  
TMF Trial Master File  
ULOQ  Upper Limit of Quantification  
US [LOCATION_002]  
VSD  Vaccine Safety Datalink  
WHO  World Health Organization  
 
 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 22 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 23 of 84 1 Introduction 
1.1 Background 
This is a study using the 2018–2019 formulations of quadrivalent inactivated influenza vaccine 
(Fluzone® Quadrivalent, Influenza Vaccine ), recombinant influenza vaccine (Flublok® 
Quadrivalent, Influenza Vaccine) , and high-dose trivalent inactivated influenza vaccine (Fluzone® 
High -Dose, Influenza Vaccine).  
Influenza viruses types A and B belong to the genus Orthomyxoviridae and are characterized as enveloped, negative-strand, segmented ribonucleic acid ( RNA) viruses. The viral envelope 
contains 2  virus-coded glycoprotein spi[INVESTIGATOR_2988], the hemagglutinin (HA) and neuraminidase (NA) 
proteins, which are key antigens in the host response to influenza virus in both natural infection  and vaccination. A third protein, M2, is a minor envelope component of the A- strain 
viruses (1). 
Influenza is transmitted through inhalation of virus-containing droplets from infected individuals. The in cubation period is usually 1 to 2 days  (2). The virus multiplies in the ciliated columnar 
epi[INVESTIGATOR_190560]- and lower- respi[INVESTIGATOR_4352], causing cellular necrosis and sloughing  (1). 
Virus shedding typi[INVESTIGATOR_644211] (within 24 hours), rapi[INVESTIGATOR_190562], and remains elevated for 1 to 2 days before rapi[INVESTIGATOR_644212]. Usually, virus shedding lasts a total of 5 to 10 days  (2). 
There is considerable variation in the severity of illness in different individuals, partly due to age, general health, and immune status relative to previous influenza infections and vaccination. The classic symptoms include rapid onset (12 hours or less) of malaise, fever, myalgia, headache, and a non-productive cough or sore throat. Most symptoms last several days, but malaise and cough may last for a week or more (2). Complications of influenza include primary viral pneumonia, 
secondary bacterial pneumonia, and exacerbation of underlying medical conditions such as chronic obstructive pulmonary disease and congestive heart failure.  
While influenza affects all age groups, the elderly , children younger than  5 years of age, and 
persons with underlying health problems are at increased risk for complications. Members of 
high-risk groups who become ill with influenza are more likely than the general population to require hospi[INVESTIGATOR_059]. Among infants and younger children, estimated rates of influenza-associated hospi[INVESTIGATOR_654737]- related complications, including 
persons aged ≥ 65 years due to immunosenescence and adults 50–[ADDRESS_878645] chronic medical conditions that put them at increased risk of severe influenza illness (3).  
Antigenic variation is an important feature of the influenza virus. The viral HA and NA surface antigens are subject to continuous and sequential evolution within immune or partially immune populations. Antigenic drift results from mutation(s) affecting the RNA segment coding for either HA or NA, but more commonly HA. As a result, there is alteration in protein structure involving 1 or a few amino acid s, resulting in minor changes in antigenicity. Antigenic variants within a 
subtype (e.g., H1 or H3) emerge and through natural selection gradually become the more 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 23 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878646] to antigenic drift, antigenic shift represents the 
emergence of completely new subtypes, typi[INVESTIGATOR_654738]. Antigenic shift 
occurs at irregular intervals and may lead to pandemics (1) (2) . While influenza B appears to be 
more genetically stable than influenza A, the dominant circulating B strain typi[INVESTIGATOR_644215]. For over a decade, both Yamagata and Victoria lineages have co -circulated 
during each season with varying prevalence (4). The large antigenic divergence between the 
[ADDRESS_878647] the other. Accordingly, switching from a trivalent vaccine to a quadrivalent vaccine is expected to prevent additional morbidity and mortality associated with mismatched influenza B strains that may occur with trivalent vaccines (4). With this in  mind, 
Fluzone Quadrivalent vaccine and Flublok Quadrivalent vaccine w ere developed. 
Vaccination with influenza vaccine is the primary method for preventing influenza and its severe complications. It has been shown to be effective in reducing influenza- associated morbidity and 
mortality in groups at increased risk for influenza- related complications such as infants and young 
children  and persons 50 years of age and older. Of note , immune responses to the vaccine are 
lower in seniors than those in young heal thy adults  (3). Strategies to improve immune responses 
to the vaccine in the elderly population could provide significant additional reductions in influenza-associated morbidity and mortality. One approach is to increase the dose of HA in inactivated vaccines. Previous studies evaluating the immune responses in terms of hemagglutination inhibit ion (HAI) antibodies with higher doses of HA per strain in different 
influenza vaccines support a dose- response effect  (5). 
Fluzone High-Dose vaccine contains [ADDRESS_878648] disease caused by [CONTACT_14302] A subtype viruses and type B viruses contained in the vaccine for  adults 18 years of age and older. Use of recombinant DNA techniques to 
produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen’s eggs. Recombinant technology also allows control over the sequence of the full-length HA produced. The recombinant proteins are highly purified and the 
vaccine contains no egg protein, preservatives or antibiotics, any of which may produce 
hypersensitivity reaction  in some individuals. 
Flublok Quadrival ent vaccine contains [ADDRESS_878649] -dose quadrivalent inactivat ed influenza vaccine ( SD-IIV4 ). The high 
purity of a recombinant antigen enables administration of a  higher concentration of HA antigen 
without a significant increase in side  effects in human subjects.  This higher dose of antigen may 
be a particular advantage to older adults whose immune responses to influenza vaccines can be suboptimal. 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 24 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 25 of 84 During this study, Fluzone Quadrivalent, Flublok Quadrivalent, or Fluzone- High -Dose vaccine 
will be administered according to the guidelines in the Prescribing Information and only to 
persons for whom it is indicated.  
The objectives of this study are to describe the safety and immunogenicity of Fluzone 
Quadrivalent vaccine in children 6 months to < 9 years of age and adults 18 to < 65 years of age, Flublok Quadrivalent vaccine in adults 18 to < 65 years of age, and Fluzone High- Dose vaccine in 
adults ≥ 65 years of age. An additional objective of the study is to provide available sera collected 
from subjects to the Center for Biologics Evaluation and Research (CBER) for further analysis by [CONTACT_38375] (WHO), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA) to support formulation recommendations for subsequent influenza vaccines.  In addition, available sera from adult subjects may be further 
analyzed by [CONTACT_654753]. 
1.1.[ADDRESS_878650] occur as a late indicator. Finally, an increased number of deaths due to pneumonia and influenza are a highly specific indicator of influenza. However, due to the reporting delay and time course from infection to death, this indicator lags behind the others  (2).  
As with other viral respi[INVESTIGATOR_18073], influenza is a seasonal disease. In the Northern Hemisphere, influenza is most likely to occur from November to April, and in the Southern Hemisphere from May to October. In tropi[INVESTIGATOR_190566], it is more endemic, with periods of 
increased activity occurring more than once a year.  
The public health impact of influenza is dramatic. During seasonal influenza epi[INVESTIGATOR_654739] 
1979–1980 through 2000–2001, the estimated annual overall number of influenza- associated 
hospi[INVESTIGATOR_275616] (US) ranged from approximately 55,000 to 431,000 per annual epi[INVESTIGATOR_901] (mean: 226,000)  (3) (6). Between the 1976–1977 season and 2006–2007 
season,  estimated annual deaths attributable to influenza ranged from 3,000 to 49,000 each 
season  (3) (7). Approximately 90% of the deaths attributed to pneumonia and influenza during 
these periods occurred among persons ≥ 65 years of age  (3). From the 1976–1977 season through 
the 2006–2007 season, an estimated yearly average of 21,098 influenza- related deaths occurred 
among adults aged ≥ 65 years, compared with an estimated 124 deaths among persons < 19 years of age and 2385 deaths among persons 19 through 64 years of age  (3) (7) .  
In the [LOCATION_002], death associated with laboratory -confirmed influenza virus infection among 
children < 18 years of age has been a nationally reportable condition since 2004. Since reporting 
began, the annual number of influenza- associated ped iatric deaths during regular influenza 
seasons has ranged from 37 to 171 deaths per season (3). However, between 15 April 2009 and 02 October 2010 (the period of the 2009 H1N1 influenza pandemic), 358 deaths attributed to 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 25 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 26 of 84 laboratory -confirmed 2009 H1N1 influenza occurred among children < 18 years of age, the 
majority of whom had 1 or more underlying medical conditions previously associated with 
conferring a greater risk for influenza complications (3). 
Based on current understanding, the epi[INVESTIGATOR_190573] B is characterized by [CONTACT_644232][INVESTIGATOR_190574] 2 –4 years. It causes infections in all age groups, including children, young adults, 
and the elderly. While influenza affects all  age groups, young children remain at increased risk 
for complications and are more likely than the general population to require hospi[INVESTIGATOR_059]. 
Influenza B has been associated with myalgia, myositis, pneumonia, and leukopenia in  children  (8) (9) (10). Influenza B infection in older adults leads to excess mortality in some annual 
epi[INVESTIGATOR_7509]. Across all ages, the burden of disease from influenza B is less than that from A/H3N2 but greater than that from A/H1N1. Overall, it is a significant cause of absenteeism, clinic visits, hospi[INVESTIGATOR_602], and deaths  (4). 
1.1.[ADDRESS_878651] of influenza is to vaccinate persons at risk each year before the onset of the influenza season, especially persons at high risk for influenza- related complications. The Advisory Committee on Im munization Practices (ACIP) of 
the CDC recommends that all eligible persons [ADDRESS_878652] influenza  (3).  
Influenza vaccine has been effective in reducing influenza-related morbidity and mortality. The effectiveness of the influenza vaccine in preventing or attenuating influenza illness depends in part on the age and immune competence of the vaccine recipi[INVESTIGATOR_644219]. Most vaccinated children and young adults develop high post-vaccination HAI antibody titers. These antibodies are protective against illness caused by [CONTACT_644233]. Elderly persons and persons with certain chronic diseases may develop lower post -vaccination antibody titers than healthy young adults and thus 
may remain susceptible to influenza-related upper respi[INVESTIGATOR_18073]. However, even if such older persons develop influenza illness despi[INVESTIGATOR_644220], the vaccine can be effective in preventing lower-respi[INVESTIGATOR_644221], thereby [CONTACT_644234][INVESTIGATOR_9017] (3) .  
In 1 meta-analysis, influenza vaccine was shown to prevent illness in 59% (95% confidence interval [CI] = 51%–67%) of adults aged [ADDRESS_878653] influenza symptoms was 73% (95% CI = 54%–84%) whereas it was 
44% (95% CI = 23%–59%) when they were not well-matched. The only large randomized 
placebo -controlled trial conducted among community-dwelling persons aged ≥ 60 years reported 
a vaccine efficacy of 58% (95% CI = 26% –77%) against serologically confirmed influenza illness  
during a season when the vaccine strains were considered to be well -matched to circulating 
strains  (3).  
Some observational studies that have provided estimates of vaccine effects for serious complications of influenza infections among community-dwelling older persons have found large 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 26 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 27 of 84 reductions in hospi[INVESTIGATOR_413337]. For example, in 1 case-control study conducted during the 
1999–2000 season in persons aged < 65 years with underlying medical conditions, vaccination 
was reported to reduce deaths attributable to any cause by 78% and reduce hospi[INVESTIGATOR_654740] 87%  (3). Recent studies 
using methods to account for unmeasured confounding factors (e.g., dementia and difficulties with self -care) have indicated that vaccine effectiveness among community -dwelling older 
persons for nonspecific serious outcomes such as pneumonia/influenza hospi[INVESTIGATOR_103151]-cause mor tality is < 10%, which is much more plausible than higher estimates from earlier 
studies (11).  
1.1.3 The Advisory Committee on Immunization Practices Recommendations  
Because children 6 through 23 months of age are at substantially increased risk for influenza-related hospi[INVESTIGATOR_602], and children 24 through 59 months of age are at increased risk for influenza- related clinic and emergency department visits, ACIP has recommended annual 
vaccination of all eligible children in these age groups. In recent years, ACIP further expanded the age groups targeted for vaccination, and now recommends that all eligible persons 6 months of age and older receive annual influenza vaccination (3) . The ACIP  continues to emphasize the 
importance of vaccinating persons ≥ [ADDRESS_878654] high- risk medical conditions  (3). 
If a child [ADDRESS_878655] year of being vaccinated. Children 6 months through 8 years of age who are adequately primed, based on influenza vaccination history, should receive 1 dose during the current season as per ACIP recommendations (3).  
1.[ADDRESS_878656]  
Vaccine Testing and Release  
Before being released for clinical use, the 2018–[ADDRESS_878657] passed all approved release-
testing requirements.  
Previous Clinical Experience : Fluzone  Vaccine 
Fluzone vaccine
 was licensed in the [LOCATION_002] in [ADDRESS_878658] also demonstrated the safety and immunogenicity, and/or effectiveness of Fluzone High-Dose and Fluzone Quadrivalent vaccines. 
Fluzone Quadrivalent Vaccine  
In pre-licensure studies, Fluzone Quadrivalent vaccine, which contains 4 influenza strains 
(A/H1N1, A/H3N2, and 2 B strains [1 each from the Yamagata and Victoria lineages]), induced 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 27 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878659] both B lineages simultaneously, without compromising vaccine safety (12) (13). 
Fluzone High- Dose Vaccine  
Fluzone High- Dose vaccine, a trivalent formulation  with 60 µg HA per viral strain, has been 
shown in pre- licensure studies to elicit a higher immune response in the elderly than does Fluzone 
vaccine (15 µg HA per viral strain) (14) (15)  (16). Solicited injection site and systemic reactions 
were reported more frequently with Fluzone High- Dose vaccine; however, these events were 
generally mild to moderate in intensity and transient. No safety concerns were identified. 
Moreover, a large -scale efficacy trial, which was conducted during 2 influenza seasons (2011 –
2012 and 2012–2013) and involved more than 30,000 persons, showed that Fluzone High- Dose 
vaccine was 24.2% more effective than Fluzone vaccine in preventing laboratory-confirmed symptomatic influenza in persons 65 years of age and older. The results of the study met the FDA- agreed criteria for demonstrating the superiority of Fluzone High- Dose vaccine compared 
with Fluzone vaccine for prevention of influenza disease in older adults  (17). 
Previous Clinical Experience: Flublok Vaccine 
Flublok vaccine (trivalent formulation) was first approved in the United S tates on 16 Jan uary 
2013 for use in adults 18–49 years of age.  L icensure was based on results of a randomized 
controlled efficacy trial  of Flublok vs placebo in 2344 subjects. The age indication was  expanded 
to include all adults 18 years of age and older in 2014 based on safety and immunogenicity data  
from 2 studies; the first study was of 869 adults 65 years of age and older, and the second was of 
602 adults 50–64 years of age.  
Flublok Quadrivalent Vaccine On 07 October 2016, the FDA licensed  Flublok Quadrivalent  vaccine for adults 18 years of age 
and older. This approval was based on 2 studies conducted during the 2014–2015 influenza 
season : (1) an immunogenicity and safety study of Flublok Quadrivalent vaccine versus  SD-IIV4 
in 1350 adults 18–49 years of age and (2) an efficacy , immunogenicity, and safety study of 
Flublok Quadrivalent vaccine versus SD -IIV4  in 9003 adults 50 years of age and older. In the 
former study ( of adults 18–49 years of age), immunogenicity of Flublok Quadrivalent vaccine 
was non- inferior to that of the SD-IIV4 comparator for 3 of the 4 antigens ; the response to the B 
Victoria lineage strain was low in both vaccine groups, making comparisons uninterpretable. In 
the latter efficacy study of adults 50 years of age and older, Flu blok Quadrivalent vaccine, 
compared to the SD-IIV4 comparator, demonstrated 30% to 43% greater efficacy in preventing 
laboratory -confirmed, protocol-defined influenza- like-illness  caused by [CONTACT_654754]. 
The most common local adverse reactions (ARs) to Flublok Quadrivalent vaccine include 
tenderness and pain at the injection site. The most common systemic reactions include headache, fatigue, myalgia, and arthralgia, with  most events being mild to moderate in severity. Safety 
profiles of Flublok influenza vaccin e and inactivated influenza vaccine (trivalent and quadrivalent 
comparisons) were demonstrated to be similar in clinical trials.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 28 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 29 of 84 1.3 Potential Benefits and Risks  
1.3.1 Potential Benefits to Subjects  
The benefit to subjects participating in this study is potential pr otection from influenza disease 
following the receipt of the 2018–[ADDRESS_878660] had no prior exposure to the 
virus antigens in the vaccine (e.g., young children)  (18). These reactions begin [ADDRESS_878661] that in elderly 
persons and in healthy young adults, split-virus influenza vaccine is not associated with highe r 
rates of systemic symptoms when compared with placebo injection  (19).  
Immediate allergic reactions (e.g., hives, angioedema, allergic asthma, and systemic anaphylaxis) occur rarely after influenza vaccination. These reactions probably result from hypersensitivity to some vaccine component  (20) (21) (22).  
Guillain -Barré syndrome (GBS) is a very rare, acute, and frequently severe polyneuropathy 
characterized by [CONTACT_654755]. The 1976 swine influenza vaccine was associated with an increased frequency of GBS. Among persons who received the swine influenza vaccine in 19 76, the rate of GBS that exceeded the background rate was < 10 cases/1,000,000 
persons vaccinated. Evidence for a causal relationship of GBS with subsequent vaccines prepared from other influenza viruses is unclear. Obtaining strong epi[INVESTIGATOR_190576] a possible limited increase in risk is difficult for such a rare condition as GBS, which has an annual incidence of 10–20 cases per 1,000,000 adults and stretches the limits of epi[INVESTIGATOR_190577] (23).  
The reasons why swine influenza vaccine triggered GBS in [ADDRESS_878662] never been discovered. In subsequent annual influenza vaccine programs in the [LOCATION_002], from 1977 to 1991, the overall relative risk estimates for GBS after influenza vaccination were slightly elevated  but were not statistically significant in any of the studies. However, in a study of the 
1992–1993 and 1993–1994 seasons, the overall relative risk for GBS was 1.7 (95% CI = 1.0–2.8; P = 0.04) during the 6 weeks after vaccination, representing approximately 1 additional case of GBS for each 1,000,000 persons vaccinated. The combined number of GBS cases peaked 2 weeks after vaccination. A meta- analysis provided a similar risk estimate for GBS following receipt of 
2009 influenza A (H1N1) monovalent inactivated influenza vaccine  (24). Thus, investigations to 
date indicate that there is no substantial increase in GBS associated with influenza vaccines (other than the swine influenza vaccine in 1976) and that, if influenza vaccine does pose a risk, it is probably slightly more than [ADDRESS_878663] of vaccination in the years after 1976, the estimated risk for GBS of approximately 1 additional case/1,000,000 persons vaccinated is substantially less than the risk 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 29 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 30 of 84 for severe influenza, which could be prevented by [CONTACT_654756] ≥ [ADDRESS_878664] medical indications for infl uenza vaccination.  
Neurological disorders temporally associated with influenza vaccination such as myelitis 
(including encephalomyelitis and transverse myelitis), optic neuritis/neuropathy, partial facial paralysis, and brachial neuritis have been reported . However, no causal relationship has been 
established. Almost all persons affected were adults, and the described clinical reactions began as soon as a few hours and as late as [ADDRESS_878665] always reported (25). 
Analysis of reports collected by [CONTACT_644238] 2010–
2011 influenza season suggested an increased risk of febrile seizures among children younger than 2 years of age who received trivalent inactivated influenza vaccine (IIV3) (26). Using data collected through the CDC- sponsored Vaccine Safety Datalink (VSD) project, Tse et al.  (27) 
found an increased risk of fever- associated seizure occurring on the day of and 1 day after 
influenza vaccination in children 6 months through 4 years of age during the 2010–2011 influenza season . The risk was higher among children who received concomitant IIV3 vaccine and 
pneumococcal conjugate vaccine (PCV) 13-valent, and peaked at approximately age 16 months (44.9 cases pe r 100,000 doses). In a subsequent study that included VSD data collected over 
5 influenza seasons (2005––2011), Duffy et al. ( 28) reported that inactivated influenza 
vaccination in children 6–23 months of age was not an independent risk factor for febrile seizures, but revealed an increased risk of febrile seizure when influenza vaccine was giv en with either 
PCV or a diphtheria-tetanus- acellular- pertussis (DTaP) -containing vaccine. The maximum 
estimated absolute excess risk due to concomitant administration of IIV3, PCV, and DTaP-containing vaccines compared with administration of these vaccines on separate days was 30 cases per 100,000 vaccinees. According to CDC, the risk of febrile seizure following influenza vaccination is small  (29). 
Cases of demyelinating disorders (e.g., incident multiple sclerosis in adults, acute disseminated encephalomyelitis, transverse myelitis), have been reported following influenza vaccines, although the Institute of Medicine concluded that the evidence is inadequate to accept or reject a causal relationship  (25).  
Cases of vasculitis have been reported following influenza immunization. A cause-and- effect 
relationship has not been determined (25).  
A Phase III study performed in persons ≥ 65 years of age demonstrated increased rates of solicited injection site and systemic reactions in subjects receiving Fluzone High- Dose vaccine co mpared 
to persons receiving Fluzone vaccine but were typi[INVESTIGATOR_352018]  (16) . Safety 
monitoring of Fluzone High- Dose vaccine during the first year after licensure indicated a higher 
than expected number of gastrointestinal events compared with standard-dose vaccine, but otherwise no new safety concerns were identified  (30).  
There may be other risks not yet identified.  
Please refer to the US Prescribing Information for the vaccine administered for other adverse 
events (AEs).  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 30 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878666] been conducted 
in the [LOCATION_002] in support of licenses held by [CONTACT_654757]. The aim of the GRC90 study is to evaluate the safety and immunogenicity of the 2018–2019 formulation of Fluzone Quadrivalent vaccine in children 6 months to < 9 years of age and in adults 18 to <  65 years or age, the 2018 –2019 formulation of Flublok Quadrivalent in adults 
18 to  < 65 years of age, and of the 2018–2019 formulation of Fluzone High- Dose vaccine in 
adults ≥ 65 years of age.  
Samples of sera from subjects will be supplied to CBER after the completion of this study (i.e., 
after the last subject completes the last study visit). In turn, CBER will distribute the sera to CDC and other WHO-collaborating laboratories for evaluation against circulating influenza viral strains. It is expected that the immunologic and surveillance data will be presented at WHO meetings where the vaccine strain selections will be made for the Southern and Northern hemispheres and at the FDA Vaccines and Rel ated Biological Products Advisory Committee 
meeting for selection of strains for influenza vaccines to be distributed in the [LOCATION_002].   
2 Study Objectives 
2.1 Observational Objectives 
2.1.1 Safety 
To describe the safety of the 2018–2019 formulation of Fluzone Quadrivalent vaccine in children 6 to < 36 months of age and 3 to < 9 years of age, and in adults 18 to < 65 years of age, the safety of the 2018–2019 formulation of Flublok Quadrivalent vaccine in adults 18 to < 65 years of age, and the safety of the 2018–2019 formulation of Fluzone High-Dose vaccine in adults ≥ 65 years of age.  
The endpoints for the observational safety objective are presented in Section [IP_ADDRESS]. 
2.1.2 Immunogenicity  
To describe the immunogenicity of the 2018–2019 formulation of Fluzone Quadrivalent vaccine 
in children 6 to < 36 months of age and 3 to < 9 years of age, and in adults 18 to  < 65 years of 
age, the immunogenicity of the 2018–2019 formulation of Flublok Quadrivalent vaccine in adults 
18 to < 65 years of age, and the immunogenicity of the 2018–2019 formulation of Fluzone High-Dose vaccine in adults ≥ 65 years of age.  
The endpoints for the observational immunogenicity objective are presented in  Section [IP_ADDRESS]. 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 31 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 32 of 84 2.1.3 Serum Collection  
To provide available sera (collected from subjects before vaccination [Blood Sample 1] and after 
final vaccination [Blood Sample 2]) to CBER for further analysis by [CONTACT_14300] , the CDC, and the 
FDA to support formulation recommendations for subsequent influenza vaccines. In addition, 
available sera from adult subjects may be further analyzed by [CONTACT_654753]. 
There are no endpoints for the serum collection objective. 
3 Investigators and Study Organization 
This study will be conducted in 3 centers in the [LOCATION_002]. Details of the study centers, the 
Investigators at each center, and the Coordinating Investigator (s) are provided  in the “ List of 
Investigators and Centers Involved in the Trial ” document.  
The Sp onsor’s Responsible Medical Officer s (the RMOs;  the persons authorized to sign this 
protocol and any amendments on behalf of the Sponsor) are  and 
, or such delegate(s) as may be identified in their absence.  
4 Independent Ethics Committee/ Institutional Review Board 
Before the investigational product can be shipped to the investigational site and before the 
inclusion of the first subject, this protocol, the informed consent form (s) (ICF [s]), assent form(s) 
(subje cts 7 to < [ADDRESS_878667] sign an assent form), subject  recruitment procedures, and any 
other written information to be provided to subjects must be approved by, and/ or receive 
favorable opi[INVESTIGATOR_35269], the appropriate Institutional Review Board(s)  (IRB [s]). 
In accordance with Good Clinical Practice (GCP) and local regulations, each Investigator and /or 
the Sponsor are responsible for obtaining this approval and/or favorable opi[INVESTIGATOR_654741]. If the protocol is subsequently amended, approval must be re-obtained for each substantial amendment. Copi[INVESTIGATOR_35271], along with information on the type, version number, and date of document, and the date of approval, must be forwarded by [CONTACT_654758] (s) (the names and qualifications of the 
members attending and voting at the meetings). 
The Investigator wi ll submit written summaries of the status of the study to the IRB (s) annually, 
or more frequently if requested. All serious adverse events (SAEs) occurring during the study that 
are related to the product administered will be reported by [CONTACT_26492] (s), 
according to the IRB policy. 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 32 of 85

[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 33 of 84 5 Investigational Plan 
5.1 Description of the Overall Study  Design and Plan  
5.1.1 Study Design 
This will be a Phase IV, multi-center, open- label study of a planned 240 subjects to describe the 
safety and immunogenicity of Fluzone Quadrivalent vaccine in children 6 months to < 9 years of 
age and adults 18 to < 65 years of age, Flublok Quadrivalent vaccine in adults 18 to < 65 years of age, and Fluzone High-Dose vaccine in adults ≥ 65 years of age.  
Using a pre-programmed interactive response technology (IRT) system, e ach subject will be 
assigned to a vaccine group based on the subject’s age at the time of enrollment. An 
approximately equal number of subjects from each group will be enrolled at each site.  
Using the IRT system, subjects 18 to < 65 years of age will be randomly assigned to either Group 3 or Group 4. E nrollment in Gr oup 3 and Group 4 will be stratified by [CONTACT_42889] 2 subgroups 
at each site so that approximately 50% of subjects at each site will be 18  to < 50 years of age and 
approximately 50% of subjects at each site will be 50 to < 65 years of age, and so that an equa l 
proportion of subjects within each age subgroup receive either Fluzone Quadrivalent or Flublok Quadrivalent vaccine.  If necessary to achieve 50% overall enrollment of subjects 50  to < 65 years 
of age and assignment of Fluzone Quadrivalent and Flublok Qua drivalent vaccines in a 1:1 ratio 
within each age subgroup (i.e., 18 to < 50 years of age and 50 to < 65 years of age), individual 
sites may be permitted to deviate from these ratios.  
• Group 1: Children 6 to < 36 months of age assigned to receive a 0.25- mL dose of Fluzone 
Quadrivalent vaccine ( 30 subjects planned) 
• Group 2: Children 3 to < 9 years of age assigned to receive a 0.5-mL dose of Fluzone 
Quadrivalent vaccine ( 30 subjects planned) 
• Group 3: Adults 18 to < 65 years of age assigned to receive a 0.5 -mL dose of Fluzone 
Quadrivalent vaccine (60  subjects planned)  
• Group 4: Adults 18 to < 65 years of age assigned to receive a 0.5-mL dose of Flublok Quadrivalent vaccine (60 subjects planned)  
• Group 5: Adults ≥ 65 years of age assigned to receive a 0.5 -mL dose of Fluzone High- Dose 
vaccine (60  subjects planned)  
5.1.2 Justification of the Study Design 
See Section 1.4 for the justification for the selection of subjects and the choice of groups. 
5.1.3 Study Plan 
All subjects will receive either a 0.25 -mL (subjects 6 to < 36 months of age [Group 1]) or a 
0.5-mL (s ubjects 3 to < 9 years of age and ≥ 18 years of age [Groups 2, 3, 4, and 5]) intramuscular 
injection of study vaccine based on their assigned group at Visit 1. For subjects 6 months to < 9 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 33 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 34 of 84 years of age for whom 2 doses of influenza vaccine are recommended per ACIP guidance, a 
second intramuscular injection of Fluzone Quadrivalent vaccine (same 0.25 -mL or 0.5- mL 
volume as administered at Visit 1) will be administered at Visit 2 (28 [window, 28 –35] days after 
Visit 1).  
Subjects 6 months to < 9 years of age (Group 1 and Group 2): blood specimens (approximately 
5 mL) will be obtained from all subjects prior to the first vaccination at Visit 1  (Day 0)  and 28 
(window, 28–35) days following the final vaccination (Visit 2, if no study vaccine is administered at Vis it 2; or Visit 3, if a second dose of study vaccine is administered at Visit 2) and assayed for 
immunogenicity. Staff will observe subjects for [ADDRESS_878668] the occurrence of any immediate unsolicited systemic AEs. Subjects’ parents/guardians will record information about solicited injection site and systemic reactions from Day [ADDRESS_878669] information about unsolicited non-serious AEs and SAEs from Visit 1 through Visit 2 for subjects receiving 1 dose of study vaccine, and from Visit 1 through Visit 3 for subjects receiving 2 doses of study vaccine. 
Subjects ≥ 18 years of age (Group 3, Group 4, and Group 5): blood specimens (approximately 
20 mL) will be obtained from a ll subjects prior to vaccination at Visit 1 and 21 (window, 21–28) 
days post- vaccination (Visit 2). Staff will observe subjects for [ADDRESS_878670] information about unsolicited non- serious AEs 
and SAEs from Visit 1 through Visit 2. 
5.1.4 Visit Procedures 
Medical procedures (injections, examinations, etc.) must be conducted by [CONTACT_654759]/credentials.  
Visit 1 (Day 0): Inclusion and Vaccination  
1) Explain the study objectives and design to the subject or subject’s parent/guardian, including 
but not limited to its objectives, design, and risks and benefits, and answer any questions the 
subject or subject’s parent/guardian may have. 
2) Obtain a written informed consent f rom the subject or subject’s parent/guardian and assent (if 
required as per IRB regulations). The Investigator or delegate will also sign and date the ICF and assent form, retain the originals, and give copi[INVESTIGATOR_654742](s) to the subject or subject’s parent/guardian. 
3) Check eligibility of the subject by [CONTACT_654760].  
4) Collect relevant demographic information (date of birth, sex, race, and ethnic origin). 
5) Obtain significant medical history (see  Section 5.2.6 f or details).  
6) For subjects 6 months to < [ADDRESS_878671] influenza vaccination history to determine vaccination sch edule (1 dose versus 2 doses) per ACIP recommendations in effect during the 
study. 
7) For subjects ≥ [ADDRESS_878672] if known. 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 34 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 35 of 84 8) Perform a directed physical examination, if indicated, based on medical history. 
9) Measure the temperature by [CONTACT_654761] (see Section [IP_ADDRESS].2) and record this 
information in the source document. If the subject has a temperature ≥ 100.4°F (38.0°C)  defer 
enrollment until the subject has been afebrile for at least 24 hours (see Section [IP_ADDRESS] ). 
10) When applicable, obtain a urine or serum pregnancy test. 
11) For subjects 6 months to < 9 years of age and adults ≥ 65 years of age : If subject meets all 
inclusion and no exclusion criteria, connect to the IRT system to enter required data to 
receive subject number and vaccine and dose to be administered based on subject’s age.  For subjects 18 to < 65 years of age: If subject meets all  inclusion and no exclusion criteria, 
contact [CONTACT_654762] . 
12) Obtain a pre-vaccination blood sample (approximately 5 mL for subjects 6 months to < 9 years of age, approximately 20 mL for subjects 
≥ 18 years of age; see  Section 7.1 f or 
detailed instructions regarding the collection of blood samples).  
13) Prepare the vaccine to be administered based on the information provided in  Section [IP_ADDRESS], 
Section [IP_ADDRESS], and Section [IP_ADDRESS].  
14) Within [ADDRESS_878673] 1 dose of assigned study vaccine intramuscularly into the anterolateral muscle of the thigh or the deltoid muscle, as appropriate (see  Section [IP_ADDRESS], Section [IP_ADDRESS], and Section [IP_ADDRESS]).   
15) Observe subject for 20 minutes following the injection for the occurrence of allergic and anaphylactic reactions and immediate injection site and systemic reactions.  
16) Provide to the subject or subject’s parent/guardian an age- appropriate diary card, a digital 
thermometer, and a flexible ruler, along with instructions for their use, to record solicited injection site and systemic reactions from Day [ADDRESS_878674]-vaccination, and unsoli cited AEs, SAEs, as well as any concomitant medications (see Section 6.7) from Visit 1 
through Visit 2. 
17) Schedule Visit 2.  
18) Remind the subject or subject’s parent/guardian that they will be contact[CONTACT_654763] [ADDRESS_878675] with them to Visit 2.  
19) Remind the subject or subject’s parent/guardian to notify the site immediately if an SAE occurs.  
20) Complete the relevant case report form s (CRF s) for this visit.  
Telephone Contact – Visit 1 + 8 (window, 8–10) Days 
Eight days after the study vaccination at Visit 1, a delegated staff member from the study site will telephone the subject or subject’s parent/guardian to perform the following: 
1) Remind the  subject or  subject’s parent/guardian to record on the diary card any AEs and any 
concomitant medications (see Secti on 6.7) from Visit 1 until Visit 2.  
2) Remind the subject or subject’s parent/guardian to notify the site immediately if an SAE 
occurs. If an SAE occurs, follow the instructions in Section 10 fo r reporting it.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 35 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 36 of 84 3) Confirm the date of the appointment of Visit 2, instruct the subject or subject’s 
parent/guardian to return at this time, and to bring the completed diary card with them to the 
study site. 
Note:  If Day [ADDRESS_878676]’s parent/guardian is not available, the study staff 
should document the attempts to make contact. 
Visit 2 (Visit 1 + 21 [window, 21–28] days) – Subjects 18 Years of Age and Older – Collection of 
Safety Information and Blood Sample  
1) Review the diary card with the subject and collect it as a source document.  
2) Review interim health history, including any AEs, medications, or therapy that occurred 
since vaccination.  
3) Obtain the seco nd blood sample (approximately 2 0 mL; see Section 7.1 f or detailed 
instructions regarding the handling of blood samples). 
4) Complete the relevant CRF s for this visit as well as the termination record in the case repor t 
book ( CRB). 
Visit 2 (Visit 1 + 28 [window, 28–35] days) – Subjects 6 Months to < 9 Years of Age Receiving 1 Dose of Influenza Vaccine – Collection of Safety Information and Blood Sample  
1) Review Diary Card [ADDRESS_878677]’s parent/guardian for accuracy  and collect it as the 
source document. 
2) Review interim health history, including any AEs, medications, or therapy that occurred since 
vaccination. 
3) Obtain the second blood sample (approximately 5 mL; see  Section 7.1 for detailed 
instructions regarding the collection of blood samples).  
4) Complete the relevant CRF s for this visit as well as the termination record in the CRB . 
Visit 2 (Visi t 1 + 28 [window, 28–35] days) – Subjects 6 Months to < 9 Years of Age Receiving 
2 Doses of Influenza Vaccine
a – Second Vaccination and Collection of Safety Information  
1) Review Diary Card [ADDRESS_878678]’s parent/guardian for accuracy and collect it as the 
source document. 
2) Review interim health history, including any AEs, medications, or therapy that occurred since vaccination. 
3) Perform a history -directed physical examination. 
4) Measure temperature by [CONTACT_654761] (see  Section [IP_ADDRESS].2) and record this 
information in the source document. If the subject has a temperature ≥ 100.4°F ( ≥ 38.0°C ) 
defer vaccination until the subject has been afebrile for at least 24 hours (see Section [IP_ADDRESS]).  
                                                 
a  As per ACIP guidance.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 36 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 37 of 84 5) Connect to the IRT system to confirm vaccine and dose to be administered based on subject’s 
age. The second vaccine dose should be the same as the first dose (i.e., same 0.25 -mL or 
0.5-mL v olume of Fluzone Quadrivalent vaccine) administered at Visit 1.  
6) Prepare the vaccine to be administered based on the information provided in Section [IP_ADDRESS]. 
7) Within [ADDRESS_878679] with the 
vaccine intramuscularly into the anterolateral muscle of the thigh or the deltoid muscle, as appropriate (Section [IP_ADDRESS]).  
8) Observe subject for 20 minutes following the injection for the occurrence of allergic and anaphylactic reactions and immediate injection site and  systemic reactions.  
9) Provide age-appropriate Diary Card [ADDRESS_878680]’s parent/guardian to record solicited injection site and systemic reactions from Day [ADDRESS_878681]-vaccination, and unsolicited AEs, SAEs, as well as any concomitant medications (see Section 6.7) from Visit 2 through Visit 3. 
10) Schedule Visit 3.  
11) Remind the subject’s parent/guardian that they will be contact[CONTACT_654763] [ADDRESS_878682] with them to Visit 3.  
12) Remind the subject’s parent/guardian to notify the site immediately if an SAE occurs.  
13) Complete the rel evant CRFs for this visit.  
Telephone Contact – Visit 2 + 8 (window, 8–10) Days – Subjects 6 Months to < 9 Years of Age 
Receiving 2  Doses of Influenza Vaccine
a 
Eight days after the study vaccination at Visit 2 (for subjects receiving a second vaccination), a delegated staff member from the study site will telephone the subject’s parent/guardian to perform the following: 
1) Remind the subject’s parent/guardian to record on the diary card any AEs and any 
concomitant medications (see Section 6.7) from Visit 2 until study termination Visit 3.  
2) Remind the subject’s parent/guardian to notify the site immediately if an SAE occurs. If an 
SAE occurs , follow the instructions in Section 10 fo r reporting it.  
3) Confirm the date of the appointment of Visit 3. Instruct the subject’s pa rent/guardian to return 
at this time and to bring the completed diary card with them to the study site. 
Note:  If Day [ADDRESS_878683]’s parent/guardian is not available, the study staff should document the attempts to make contact. 
                                                 
a  As per ACIP guidance.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 37 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 38 of 84 Visit 3 (Visit 2 + 28 [window, 28–35] days) – Subjects 6 Months to < 9 Years of Age Receiving 
2 Doses of Influenza Vaccinea – Collection of Safety Information and Blood Sample  
1) Review Diary Card [ADDRESS_878684]’s parent/guardian for accuracy and collect it as the 
source document. 
2) Review interim health history, including any AEs, medications, or therapy that occurred since 
vaccination. 
3) Obtain blood sample (approximately 5 mL; see Section 7.1 f or detailed instructions regarding 
the collection of blood samples). 
4) Complete the relevant CRFs for this visit as well as the termination record in the CRB. 
Collection of Diary Cards  
If the  subject or subject’s parent/guardian does not return for Visit [ADDRESS_878685]’s parent/guardian by 
[CONTACT_756]. During the telephone call, the subject or subje ct’s parent/guardian will be reminded to 
return the diary card to the study site. Telephone calls will be recorded on the subject’s source documents. If study personnel are unable to contact [CONTACT_35323]’s parent/guardian by [CONTACT_97266] 3 atte mpts, study personnel will follow instructions given in Section 5.2.9. 
Follow-up of S ubjects With Related AEs or W ith AEs That Led to Study/Vaccination 
Discontinuation:  
Unless a subject or subject’s parent/guardian refuses further contact, a subject who experiences an AE (whether serious or non-serious) during the study must be followed until the condition resolves, becomes stable, or  becomes chronic (even after the end of the subject’s participation in 
the study) if either  of the following is true: 
• The AE is considered by [CONTACT_35326]. 
• The AE caused the discontinuation of the subject from the study or from vaccination. 
5.1.[ADDRESS_878686] been obtained. 
Planned study  period - FVFS (first visit, first subject) to LVLS (last visit, last subject):  
September 2018 to December 2018 Planned end of study: December 201 8 
Planned date of final clinical study report: approximately 10 months after LVLS 
                                                 
a  As per ACIP guidance  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 38 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 39 of 84 5.1.6 Early Safety Data Review 
This study will not include an early review of safety data.  However, it may be interrupted at any 
time if new data about the investigational products become available, and/or on advice of the 
Sponsor, the IRB(s), or the FDA.  
If the study is prematurely ter minated or suspended, the Sponsor will promptly inform the 
Investigators, the IRB(s), and the regulatory authorities of the reason for termination or 
suspension. If the study is prematurely terminated for any reason, the Investigator will promptly 
inform the study subjects or subjects’ parents/guardians, as appropriate, and should assure appropriate therapy and follow-up. 
5.2 Enrollment and Retention of Study Population  
5.2.1 Recruitment Procedures 
Subjects may be recruited from the general population. The site will ensure that any advertisements used to recruit subjects (informational brochures, parent letters, posters, and other advertisements) are submitted to [COMPANY_011] Pasteur prior to submission to the IRB(s) for approval.  
5.2.[ADDRESS_878687] voluntarily confirms his or her willingness to participate in a particular study, or a parent/guardian confirms their willingness to allow their 
child to participate in a particular study . Informed consent must be obtained before any study 
procedures are performed. The process is documented by [CONTACT_3553] a written, signed, and dated ICF. In addition to the ICF that is signed by [CONTACT_35323]’s parent/guardian, subjects 
7 to < [ADDRESS_878688] , or the 
parent(s)/guardian(s) (of subjects 6 months to < 9 years of age) must be informed by [CONTACT_654764], and must have sufficient time and opportunity to ask any questions. The same must also be done for subjects 7 to < [ADDRESS_878689]’s willingness to continue 
participation in the study, or the willingness of a parent/guardian ( of subjects 6 months to < 9 years 
of age ) to have their child continue participation in the study, this will be communicated to the 
subject or subject’s parent/guardian (as appropriate) in a timely manner. Such information will be 
provided via a revised ICF or an addendum to the original ICF (and assent form) . 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 39 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 40 of 84 Informed consent forms and assent forms will be provided in duplicate, or a photocopy of the 
signed consent /assent  will be made. The original will be kept by [CONTACT_737], and the copy 
will be ke pt by [CONTACT_35323]’s parent/guardian.  
Documentation of the consent process should be recorded in the source documents. 
5.2.[ADDRESS_878690] fulfill all of the following criteria to be eligible for study  enrollment: 
1) Aged 6 months to < 9 years or ≥ [ADDRESS_878691] study vaccination (study product 
administration).a 
2) For subjects 6 to < 12 months of age, born at full term of pregnancy (≥ 37 weeks) and with a 
birth weight ≥ 2.5 kg (5.5 lbs). 
3) Informed consent form has been signed and dated by [CONTACT_1766] ≥ 18 years of age.  
4) Assent form has been signed and dated by [CONTACT_1766] 7 to < 9 years of age, and ICF  has been 
signed and dated by [CONTACT_7078](s) or guardian(s) for subjects 6 months to < 9 years of age.  
5) Subject and parent/guardian (of subjects 6 months to < 9 years of age) are able to attend all scheduled visits and to comply with all study procedures.  
5.2.5 Exclusion Criteria  
An individual fulfilling any of the following criteria is to be excluded from study enrollment: 
1) Subject is pregnant, or lactating, or of childbearing potential and not using an effective 
method of contraception or abstinence from at least [ADDRESS_878692] 1 year, or surgically sterile.  
2) Participation at the time of study enrollment (or in th e [ADDRESS_878693] study  
vaccination) or planned participation during the present study period in another clinical study 
investigating a vaccine, drug, medical device, or medical procedure.   Note:  Subjects may be considered eligible for enrollment if no intervention for the other 
study occurred within the [ADDRESS_878694] would complete safety surveillance for the present study. 
                                                 
a  “6 months to < 9 years ” means from the 6 month after birth to the day before the  9th year. “ ≥ 18 years ” means 
from the day of the 18th  birthday onwards.  
b  Pre-menarche females will declare by [CONTACT_35330]. If a young female 
subject reaches menarche during the study, then she is to be considered as a woman of childbearing potential from 
that time forward . 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 40 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 41 of 84 3) Receipt of any vaccine in the [ADDRESS_878695] study  vaccination, or planned receipt 
of any vaccine before Visit 2 for subjects receiving 1  dose of influenza vaccine or Visit 3 for 
subjects receiving 2 doses of influenza vaccine. 
4) Previous vaccination against influenza (in the 2018–2019 influenz a season) with either study 
vaccine or another vaccine.  
5) Receipt of immune globulins, blood, or blood-derived products in the 3 months preceding 
planned inclusion. 
6) Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the 6 months preceding planned inclusion; or long- term systemic corticosteroid therapy 
(prednisone or equivalent for more than 2 consecutive weeks within the 3 months preceding planned inclusion). 
7) Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to study vaccine or to a vaccine containing any of the same substances.   Note:  The list of vaccine components is included in the Prescribing Information for each 
study vaccine. 
8) Thrombocytopenia, which may be a contraindication for intramuscular vaccination, at the discretion of the Investigator.  
9) Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination.  
10) Deprived of freedom by [CONTACT_29511], or in an emergency setting, or hospi[INVESTIGATOR_29476]. 
11) Current alcohol abuse or drug addiction. 
12) Chronic illness that, in the opi[INVESTIGATOR_689], is at a stage where it might interfere with study conduct or completion.
a 
13) Moderate or severe acute illness/infection (according to Investigator judgment) on the day of planned vaccination or febrile illness (temperature ≥ 100.4°F [38.0°C]). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided. 
14) Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study (subjects ≥ 18 yea rs of age) or identified as an immediate 
family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study (all subjects). 
15) History of serious AR to any influenza vaccine.  
                                                 
a  Chronic il lness may include, but is not limited to, cardiac disorders, renal disorders, autoimmune disorders, 
diabetes , psychomotor diseases, and known congenital or genetic diseases  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 41 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 42 of 84 16) Personal h istory of GBS. 
17) Any condition that in the opi[INVESTIGATOR_35261] a health risk to the subject if 
enrolled or could interfere with the evaluation of the vaccine. 
18) Personal history of clinically significant developmental delay (at the discretio n of the 
Investigator), neurologic disorder, or seizure disorder. 
19) Known seropositivity for human immunodeficiency virus, hepatitis B, or hepatitis C. 
Note: Subjects enrolled into this study will not be prohibited from donating blood for non-interventional studies or other purposes. 
5.2.[ADDRESS_878696] 
and ongoing. Any such conditions will be documented in the source document. Significant (clinically relevant ) med ical history (reported as diagnosis) including conditions /illnesses for 
which the subject is or has been followed by a physician or conditions /illnesses that could resume 
during the course of the study or lead to an SAE or to a repetitive outpatient care will be collected in the CRB. The significant medical history section of the CRB contains a core list of body 
systems and disorders that could be used  to prompt comprehensive reporting, as well as space for 
the reporting of specific conditions and illnesse s. 
For each condition, the data collected will be limited to:  
• Diagnosis (this is preferable to reporting signs and symptoms) 
• Presence or absence of the condition at enrollment  
The reporting of signs and symptoms in lieu of a diagnosis is strongly discouraged. 
Dates, medications, and body systems are not to be recorded, and the information collected will not  
be coded. Its purpose is to assist in the later interpretation of safety data collected during the 
study. 
5.2.7 Contraindications for Subsequent  Vaccinations  
[IP_ADDRESS] Temporary Contraindications 
Should a subject experience [ADDRESS_878697] still be within the timeframe for 
vaccination indicated in the  Table of Study Procedures . 
• Febrile illness (temperature ≥ 100.4°F [≥ 38.0°C] ) or moderate or severe acute 
illness /infection on the day of vaccination, according to Investigator judgment  
[IP_ADDRESS] Definitive Contraindications  
Should a subject experience [ADDRESS_878698] dose of study vaccine, the Investigator will not administer the second dose of vaccine that has been allocated for 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 42 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 43 of 84 use in the study (i.e., study vaccine); however, the Investigator may administer a second dose of 
licensed, non -study influenza vaccine in accordance with standard clinical care.  
Definitive contraindications include but are not limited to:  
1) An anaphylactic or other significant allergic reaction to the previous dose of vaccine.  
2) Receipt of any non-study vaccine (including a non-study dose of 2018–2019 influenza 
vaccine), immune globulins, blood, or blood-derived products between Visit 1 and Visit 2. 
3) Bleeding disorder, receipt of anticoagulants, or thrombocytopenia, which may be a contraindication for intramuscular vaccination, at the discretion of the Investigator.  
4) Development of any condition that in the opi[INVESTIGATOR_35261] a health risk to the subject or could interfere with the evaluation of t he study vaccine (including 
GBS, clinically significant developmental delay, neurologic disorder, seizure disorder, human immunodeficiency virus infection, hepatitis B, or hepatitis C). 
5) Development of an immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy; or receipt of long- term systemic 
corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks). 
6) Adverse events that are considered a contraindication for further participati on in the study. 
Subjects with a definitive contraindication will continue to be followed up for the study-defined safety and immunogenicity assessments, as applicable.  Therefore, in this study subjects with a 
definitive contraindication will be discontinu ed from the study (and, accordingly, will not have a 
post-vaccination blood sample collected), but will continue to be followed for study-defined safety assessments.  
5.2.8 Conditions for Withdrawal  
Subjects or subjects’ parents/guardians will be informed that they have the right to withdraw or 
withdraw their child  from the study at any time.  
A subject may be withdrawn from the study:  
• At the discretion of the Investigator or Sponsor due to safety concerns (withdrawal) without 
the subject’s or parent’s/guardian’s  permission.  
• At the request of the subject or parent/guardian (dropout).  
The following will result in automatic withdrawal or exclusion of a subject from the study: 
• Significant non-compliance with the protocol, based on the Investigator’s judgment 
The reason for a withdrawal or dropout should be clearly documented in the source documents 
and in the CRB .  
The Investigator must determine whether voluntary withdrawal is due to safety concerns (in which case, the reason for discontinuation will be noted as “Adverse Event”) or for another reason . 
Withdrawn subjects will not be replaced. 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 43 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878699] to Follow- up Procedures  
In the case of subjects who fail to return for a follow-up examination, documented reasonable 
effort (i.e., documented telephone calls and certified mail) should be undertaken to locate or recall them, or at least to determine their health status while fully respecting their rights. These efforts should be documented in the CRB and in the source documents. 
5.2.[ADDRESS_878700] significant (refer to the CRB  completion instructions  for additional details and 
examples) : 
Adverse Event To be used when the subject is permanently terminated from the study 
because of an AE (including an SAE), as defined in  Section [IP_ADDRESS] . 
This category also applies if the subject experiences a definitive contraindication that is an SAE or AE. 
Lost to Follow-up To be used when the subject cannot be found or contact[CONTACT_35331][INVESTIGATOR_654743]/her before the date of his/her planned last visit, as 
outlined in Section 5.2.9. The certified letter was sent by [CONTACT_654765], and the subject or parent/guardian 
did not give any other news and did not come to any following visit.  
Protocol Deviation  To be used:  
• In case of significant noncompliance with the protocol 
(e.g., deviation of the Inclusion/Exclusion criteria, non -compliance 
with time windows, blood sampling or vaccination refusal,  missed 
injection/treatment, or error in the vaccine/treatment administration). 
• If the subject experiences a definitive contraindication that is a 
protocol deviation.  
• The subject or the parent/guardian signed the certified letter sent by 
[CONTACT_654766].  
Withdrawa l by [CONTACT_654767]/Guardian/Legally 
Acceptable Representative To be used:  
• When the subject or parent/guardian indicated unwillingness to 
continue in the study 
• When the subject or parent/guardian made the decision to 
discontinue participation in the study  for any personal reason other 
than an SAE/AE (e.g ., subject is relocating, inform consent 
withdrawal)  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 44 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878701]’s status at the end of the study is “Withdrawal by [CONTACT_654767]/Guardian/Legally Acceptable Representative”, the site will attempt to contact [CONTACT_654768]. 
5.2.[ADDRESS_878702] 1 dose of the study 
vaccine(s) has been administered, the subject will not be discontinued from the study, but no 
further vaccination wil l be administered until after delivery (if applicable and still within the study 
vaccination window) . However, the subject will be followed for safety assessment (and may be 
followed for immunogenicity assessment, if applicable). 
All pregnancy cases should be reported if they occurred during the study. To report the pregnancy 
case, the Investigator must fill out Pregnancy Reporting forms in the electronic data capture 
(EDC) system and inform the Sponsor within [ADDRESS_878703] fill out a paper Pregnancy Reporting 
Form (provided by [CONTACT_35337]) and inform the Sponsor within [ADDRESS_878704] to obtain information about the outcome 
(i.e., details about the delivery and the newborn, or about pregnancy termination) and must update 
the Pregnancy Reporting forms  even after the end of the study. Thi s information should be 
provided to the Sponsor within 1 month of delivery. 
Pregnancy itself is not considered an AE, but any complications during pregnancy are to be 
considered as AEs, and in some cases could be considered SAEs. Spontaneous abortions, blighted ovum, fetal death, stillbirth, and congenital anomalies reported in the baby [CONTACT_35338], and the information should be provided to the Global Pharmacovigilance & Epi[INVESTIGATOR_623] (GPE) Department regardless of when the SAE occurs (e.g., even after the end of the study ). 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 45 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 46 of 84 5.3 Safety Emergency Call  
If, as per the Investigator ’s judgment, a subject experiences a medical emergency, the Investigator 
may contact [CONTACT_1034]’ s RMO s for advice on study-related medical question or problem. The 
RMOs will be available [ADDRESS_878705] the need to report an SAE. The Investigator is still required to 
follow the protocol -defined process for reporting SAEs to the GP E Department (Please refer to  
Section 10 ). 
5.[ADDRESS_878706] the earlier version. All substantial amendments (e.g., those that affect the conduct of the study or the safety of 
subjects) require IRB approval, and must also be forwarded to regulatory authorities. 
An administrative  amendment to a protocol is one that modifies some administrative , logistical, or 
other aspect of the study but does not affect its scientific quality or have an impact on the 
subjects’ safety. Regulatory authorities need only be notified about administrative changes. 
Administrative changes do not require IRB approval; however, the IRB(s) must be notified 
whenever such a change is made.  
The Investigator is responsible for ensuring that changes to an approved study, during the period for which IRB approval has already been given, are not initiated without IRB review and approval, except to eliminate apparent immediate hazards to subjects.  
5.[ADDRESS_878707] resulting from this or 
any other studies become available; or for administrative reasons; or on advice of the Sponsor, the Investigators, the I RB(s), or the governing regu latory authorities in the country where the study is 
taking place .  
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the 
Investigators, the IRB(s), the regulatory authorities, and any contract research organization(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_25435].  The Investigator shall promptly inform the study subjects or subjects’ 
parents/guardians, as appropriate, and should assure appropriate subje ct therapy and/or follow- up. 
6 Vaccines Administered 
Subjects 6  to < 36 months of age and subjects 3 to < 9 years of age will be administered Fluzone 
Quadrivalent vaccine,  subjects 18 to < 65 years of age will be administered either Fluzone 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 46 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 47 of 84 Quadrivalent vaccine or Flublok Quadrivalent vaccine, and subjects ≥ 65 years of age will be 
administered Fluzone High- Dose vaccine.  
• Fluzone Quadrivalent vaccine, pediatric dose (subjects 6  to < 36 months of age):  
7.5 µg/HA of each antigen per 0.25-mL dose (total HA content per dose: 30 µg) 
• Fluzone Quadrivalent vaccine (subjects 3 to < 9 years of age and 18 to < 65 years of age):  
15 µg/HA of each antigen per 0.5-mL dose (total HA content per dose: 60 µg) 
• Flublok Quadrivalent vaccine (subjects 18 to < 65 years of age): 45 µg/HA of each antigen per 0.5-mL dose (total HA content per dose: 180  µg) 
• Fluzone High -Dose  vaccine (subjects ≥ 65 years of age): 
60 µg/HA of each antigen per 0.5-mL dose (total HA content per dose: 180 µg) 
Subjects will receive an intramuscular inject ion of the product that they are assigned to receive. 
For subjects 6 months to < [ADDRESS_878708] during the study. If 2 doses of influenza vaccine are indicated, 1 dose will be administered during Visit 1 and the second dose (same 0.25- mL or 
0.5-mL volume of Fluzone Quadrivalent vaccine as administered at Visit 1) will be administered 
approximately 28 days later, during Visit 2. 
6.1 Identity of the Investigational Produc ts  
The 2018–2019 formulations of Fluzone Quadrivalent (0.25-mL and 0.5- mL pre -filled syringe 
presentations) and Fluzone High- Dose vaccines are sterile suspensions prepared from influenza 
viruses propagated in embryonated chicken eggs. The virus-containing fluid is harvested and the virus inactivated with formaldehyde. The influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted producing a split antigen. The split antigen is then suspended in sodium phosphate-buffered isotonic sodium chloride solution. Neither antibiotics nor preservatives are used in the manufacture of the vaccine formulations used in this study. Fluzone Quadrivalent and Fluzone High-Dose vaccines are clear and slightly opalescent in color.  
The 2018–[ADDRESS_878709] cell line ( expresSF+
®) that is derived from 
Sf9 cells of the fall armyworm, Spodoptera frugiperda (which is related to moths, caterpi[INVESTIGATOR_36523] , and 
butterflies), and grown in serum- free medium composed of chemically -defined lipi[INVESTIGATOR_805], vitamins, 
amino acids, and mineral salts. Each of the 4 HAs is expressed in this cell line using a baculovirus 
vector ( Autographa californica nuclear polyhedrosis virus), extracted from the cells with Triton 
X-[ADDRESS_878710] 1  
Fluzone Quadrivalent vaccine, No Preservative: Pediatric Dose (0.25 -mL dose),  
2018–2019 formulation  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 47 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 48 of 84 or 
Fluzone Quadrivalent vaccine, No Preservative (0.5 -mL dose), 2018–2019 formulation  
[IP_ADDRESS] Composition  
Each 0.25-mL dose contains 7.5 µg HA of each antigen, and each 0.5-mL dose contains 
15 µg  HA of each antigen: 
• A/Michigan/45/2015 (H1N1) 
• A/Singapore/INFIMH -16-0019/2016 (H3N2)  
• B/Maryland/15/2016 (B Victoria lineage) (a B/Colorado/06/2017- like virus) 
• B/Phuket/3073/2013 (B Yamagata lineage) 
[IP_ADDRESS] Preparation and Administration  
Fluzone Quadrivalent vaccine is a liquid preparation; as such, no diluent is required. This product is provided in 0.25-mL and 0.5- mL, pre -filled, single- dose syringes. The vaccine will be 
administered intramuscularly into the anterolateral muscle of the thigh or the deltoid muscle, as appropriate. The vaccine must be administered within [ADDRESS_878711] label con tent (see  Section 6.3.1) , and extraneous particulate matter and/ or discoloration, 
whenever solution and container permit. If any of these conditions exists, the vaccine must not be administered ; another dose is to be used, and the event is to be reported to the Sponsor.  
Subjects must be kept under observation for 20 minutes after each vaccination to ensure their 
safet y, and any reactions during this period will be documented in the CRB. Appropriate medical 
equipment and emergency medications, including epi[INVESTIGATOR_238] (1:1000), must be available on site 
in the event of an anaphylactic, vasovagal, or other immediate allergi c reaction.  
[IP_ADDRESS] Dose Selection and Timing  
Fluzone Quadrivalent vaccine will be administered  at Visit 1  (Day 0) as a single 0.25-mL dose to 
subjects 6 to < 36 months of age (Group 1), and as a 0.5- mL dose to subjects 3 to < 9 years of age  
(Group 2) and subjects 18 to < 65 years of age (Group 3) assigned to receive this vaccine. For 
subjects 6 months to < [ADDRESS_878712] dose will be administered at Visit 2 (28 [window, 28 –35] days after Visit  1). 
6.1.[ADDRESS_878713] 2  
Flublok Quadrivalent vaccine, 2018–2019 formulation 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 48 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 49 of 84 [IP_ADDRESS] Composition  
Each 0.5-mL dose contains 45 µg recombinant HA of each antigen:  
• A/Michigan/45/2015 (H1N1) 
• A/Singapore/INFIMH -16-0019/2016 (H3N2)  
• B/Maryland/15/2016 (B Victoria lineage) (a B/Colorado/06/2017- like virus) 
• B/Phuket/3073/2013 (B Yamagata lineage)  
[IP_ADDRESS] Preparation and Administration  
Flublok Quadrivalent vaccine is a liquid preparation; as such, no diluent is required. This product 
is provided in 0.5-mL, pre- filled, single -dose syringes. T he vaccine will be administered 
intramuscularly into the deltoid of choice using a needle of appropriate length. To ensure intramuscular vaccination, the subject will be instructed to relax the arm; the needle will be inserted straight into the deltoid muscle, centered between the shoulder and the axilla and midway between the posterior and anterior aspects of the arm. The vaccine must be administered within 
[ADDRESS_878714] in Section [IP_ADDRESS]. 
[IP_ADDRESS] Dose Selection and Timing  
Flublok Quadrivalent vaccine will be administered as a single 0.5 -mL dose given at Visit 1 
(Day  0) to subjects 18 to < 65 years of age who are assigned to receive this vaccine (Group 4).  
6.1.[ADDRESS_878715] 3  
Fluzone High-Dose vaccine, 2018–2019 formulation 
[IP_ADDRESS] Composition  
Each 0.5 mL dose contains 60 µg HA of each antigen: 
• A/Michigan/45/2015 (H1N1) 
• A/Singapore/INFIMH -16-0019/2016 (H3N2)  
• B/Maryland/15/2016 (B Victoria lineage) (a B/Colorado/06/2017- like virus) 
[IP_ADDRESS] Preparation and Administration  
Fluzone High- Dose vaccine is a liquid preparation; as such, no diluent is required. This product is 
provided in 0.5-mL, pre- filled, single -dose syringes. T he vaccine will be administered 
intramuscularly into the deltoid of choice using a needle of appropriate length. To ensure 
intramuscular vaccination, the subject will be instr ucted to relax the arm; the needle will be 
inserted straight into the deltoid muscle, centered between the shoulder and the axilla and midway 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 49 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878716] in Section [IP_ADDRESS]. 
[IP_ADDRESS] Dose Selection and Timing  
Fluzone High- Dose vaccine will be administered as a single 0.5 -mL dose given at Visit 1 ( Day 0 ) 
to subjects ≥ 65 years of age assigned to receive this vaccine (Group 5).  
6.1.[ADDRESS_878717] Logistics  
6.3.1 Labeling and Packaging 
All study vaccines will be supplied by [CONTACT_1034]. Fluzone Quadrivalent, Flublok Quadrivalent, 
and Fluzone High -Dose vaccines will be supplied with their manufacturer’s commercial labeling 
and packaging. 
6.3.[ADDRESS_878718] Shipment, Storage, and Accountability  
[IP_ADDRESS] Product Shipment  
The Clinical Logistics Coordinator will contact [CONTACT_29517] a designee to determine the 
dates and times of delivery of products. 
Each vaccine shipment will include a temperature-monitoring device to verify maintenance of the 
cold chain during transit. On delivery of the product to the site, the person in charge of product receipt will follow the instructions given in the Operating Guidelines, including checking that the 
cold chain was maintained during shipment (i.e., verification of the temperature recorders). If there is an indication that the cold chain was broken, this person should immedi ately quarantine 
the product, alert the [COMPANY_011] Pasteur  representative, and request authorization from [COMPANY_011] Pasteur  
to use the product. 
[IP_ADDRESS] Product Storage  
The Investigator will be personally responsible for product management or will designate a staff 
member  to assume this responsibility.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 50 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878719] with restricted access. Vaccines will be stored 
in a refrigerator at a temperature ranging from +2°C to +8°C. The vaccines must not be frozen.  
The temperature must be monitored and documented (see the Operating Guidelines) for the entire 
time that the vaccine is at the study site. In case of accidental freezing or disruption of the cold 
chain, vaccines must not be administered and must be quarantined, and the Investigator or 
authorized designee should contact [CONTACT_35340].  
[IP_ADDRESS] Product Accountability  
The person in charge of product management at the site will maintain records of product delivery 
to the study site, product inventory at the site, the dose(s) given to each subject, and the disposal of or return to the Sponsor of unused doses.  
The necessary information on the product labels is to be entered into the source document and the 
CRB. If applicable, information may also be enter ed into the subject’s vaccination card. 
The Sponsor’s monitoring staff will verify the study  site’s product accountability records against 
the record of administered doses in the CRBs and the communication from the IRT  system . 
In case of any expected or po tential shortage of product during the study, the Investigator or an 
authorized designee should alert the [COMPANY_011] Pasteur representative as soon as possible, so that a shipment of extra doses can be arranged.  
6.3.3 Replacement Doses 
If a replacement dose is required (e.g., because the syringe broke or particulate matter was observed in the syringe), the site personnel must either contact [CONTACT_35341], or follow the instructions given in the Operating Guidelines. 
6.3.[ADDRESS_878720] accountability will be verified throughout the study period. 
6.3.5 Recall of Products  
If the Sponsor makes a decision to launch a retrieval procedure, the Investigator(s) will be 
informed of what needs to be done. 
6.4 Blinding and Code -breaking Procedures  
This is an open -label study. 
6.5 Randomization and Allocation Procedures  
On the day of enrollment, subjects who meet all inclusion criteria and no exclusion criteria will be 
assigned to 1 of 5 vaccine groups (6 to < 36 months of age, Fluzone Quadrivalent vaccine [Group 1], 3 to < 9 years of age, Fluzone Quadrivalent vaccine [Group 2], 18 to < 65 years of age, 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 51 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 52 of 84 Fluzone Quadrivalent vaccine [Group 3], 18 to < 65 years of age, Flublok Quadrivalent vaccine 
[Group 4], or ≥ 65 years of age, Fluzone High- Dose vaccine [Group 5]) ; see Section [ADDRESS_878721] to the IRT system, 
enter the identification and security information, and confirm a minimal amount of data (including 
the number of doses) in response to IRT system prompts. The IRT system will then provide the subject number and vaccine and dose to be administered based on subject’s age and have the site staff confirm it. Subjects 18 to < [ADDRESS_878722] of a 12- digit string (a [ADDRESS_878723] identifier connected by “-”). For 
example, Subject  8400001-[ADDRESS_878724] enrolled in center number 1 in the U nited 
States (840 being the US country code). Subject numbers should not be reassigned for any reason. 
The randomization codes will be kept securely in the IRT.  
6.6 Treatment Compliance 
The following measures will ensure that the vaccine doses administered comply with those planned, 
and that any non- compliance is documented so that i t can be accounted for in the data analyses: 
• All vaccinations will be administered by [CONTACT_9260] 
• The person in charge of product management at the site will maintain accountability records 
of product delivery to the study site, product inventory at the site, dose(s) given to each subject, and the disposal of unused or wasted doses 
6.7 Concomitant Medications  and Other Therapi[INVESTIGATOR_35274], ongoing medications and other therapi[INVESTIGATOR_014] (e.g., blood products) should 
be recorded in the source document as well as new medications prescribed for new medical conditions/AEs during study participation.  
Documentation in the CRB of ongoing concomitant medication(s)  will be limited to specific 
categories of medication (s) of interest beginning on the day of first vaccination. This may include 
medication s of interest  that were started prior to the day of vaccination. 
Reportable medications  will be collected in the CRB from the day of each vaccination to the  end 
of the solicited and unsolicited follow-up period (i.e., from Visit 1 through Visit 2 for subjects 
receiving 1 dose of study vaccine or from Visit 1 through Visit 3 for subjects receiving 2 doses of study vaccine).  
Reportable medications include medi cations that impact or may impact the consistency of the safety 
information collected after any vaccination and/or the immune  response to vaccination. Three 
standard categories of reportable medications are defined:  
• Category 1: medications impacting or that may have an impact on the evaluation of safety 
(e.g., antipyretics, analgesics, and non- steroidal anti- inflammatory drugs [NSAIDs]). Topi[INVESTIGATOR_654744]/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 52 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 53 of 84 analgesics should NOT  be applied at the site of vaccination; however, if they are applied 
inadvertently to the vaccination site, they should be recorded as a Category 1 medication in 
this specific instance, not as a Category 2 medication . 
• Category 2: medications impacting or that may have an impact on the immune response (e.g., other vaccines, blood products and immune globulins , antibiotic classes that may 
interfere with bioassays used by [CONTACT_644243] [GCI] department , immune -
suppressors, immune-modulators with immunosuppressive properties, anti-proliferative drugs such as DNA synthesis inhibitors ).  
• Category 3: medications impacting or that may have an impact on both safety and immune 
response (e.g., steroids/corticosteroids ). 
The information reported in the CRB for each reported medication will be limited to: 
• Trade n ame 
• Origin of prescription:  prophylaxis ( Yes/No ). Medication(s) prescribed for AE prophylaxis 
will be recorded in the Action Taken of the AE collection tables. 
• Medication category  (1, 2, or 3) 
• Start and stop dates  
Dosage and administration route, homeopathic medication, topi[INVESTIGATOR_211251], as well as 
topi[INVESTIGATOR_2855], ophthalmic, and ear treatment s will not be recorded.  
Medication s given in response to an AE will be captured in the “Action Taken” section  of the AE 
CRF  only. No details will be recorded in the concomitant medication CRF  unless  the medication (s) 
received belongs to 1 of the prelisted categories. Medications will not be coded.  
7 Management of Samples  
Blood samples for the assessment of antibody responses will  be collected at Visit 1 and at Visit 2 
for subjects receiving 1 dose of study vaccine or at Visit 1 and Visit 3 for subjects receiving 2 doses of study vaccine. See the Table of Study Procedures and Section 5.1.3 for  details of the 
sampling schedule. 
7.1 Sample Collection  
A total of 2 blood samples (each approximately 5 mL for subjects 6 months to < 9 years of age or approximately 20 mL for subjects 
≥ 18 years of age) will be collected from all subjects. The first 
blood sample will be collected at Visit 1 prior to vaccination. The second blood sample will be collected at Visit 2, if no study vaccine is administered at Visit 2; or at Visit 3, if study vaccine is 
administered at Visit 2. Blood will be collected in tubes provided by [CONTACT_211280]. Immediately prior to the blood draw, the staff member performing the procedure will verify the subject’s identity; will verify  the assigned subjec t’s number on the pre- printed label that 
contains that subject’s number and the sampling stage; and will attach the label to the tube. Blood is to be taken from the limb opposite to the one that will be u sed for vaccination , if possible. 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 53 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 54 of 84 7.2 Sample Preparation  
Detailed instructions on how to prepare blood samples for assessment of immune response are 
contained in the Operating Guidelines provided to the site. An overview of the procedures is 
provided here. 
Following the blood draw, the tubes are to be left undisturbed, positioned vertically and not 
shaken, for a minimum of 1 hour and a maximum of 24 hours to allow the blood to clot. Samples 
can be stored at room temperature for up to 2 hours; beyond [ADDRESS_878725] be refrigerated at a temperature of +2°C to +8°C up to a maximum of [ADDRESS_878726]’s number, and the 
sampling stage (see Section 7.1).   
The subject’s number and the date of sampling, the number of aliquots obtained, and the subject 
or subject’s parent’s/guardian’s consent for future use of his/her samples are to be specified on a sample identification list. All these items, as well as the date and time of preparation, are to be 
recorded in the source document. Space is provided on the sample identification list for comments on the quality of samples. 
7.3 Sample Storage and Shipment  
During storage, serum tubes are to be kept in a freezer whose temperature is set and maintained at -20°C or below. The temperature will be monitored and documented on the appropriate form during the entire study. If it rises above -10°C for any period of time, the Clinical Logistics 
Coordinator must be notified. See the Operating Guidelines for further d etails.  
Samples will be shipped to GCI at [COMPANY_011] Pasteur. The address is provided in the Operating Guidelines.  
Shipments to the laborator y (GCI)  will be made only after appropriate monitoring, and following 
notification of the Clinical Logistics Coordinator. Sera will be shipped frozen, using dry ice to 
maintain them in a frozen state, in the packaging container provided by [CONTACT_21440]. Again, temperatures will be monitored. Shipments must be compliant with the United Nations Class 6.2 specifications and t he International Air Transport Association  602 packaging instructions. 
7.4 Future Use of Stored Serum Samples for Research  
Any unused part of the serum samples will be securely stored at the [COMPANY_011] Pasteur  serology 
laboratory (GCI) for at least [ADDRESS_878727] license approval in the relevant market areas has 
been obtained for the vaccine being tested. 
Subjects or subjects’ parents/guardians will be asked to indicate in the ICF whether they will 
permit the future use of any unused stored serum samples for other tests. If they refuse 
permission, the samples will not be used for any testing other than that directly related to this study. If they agree to this use, they will not be paid for giving permission. Anonymity of samples will be ensured. The aim of any possible future research is unknown today, and may not be related 
to this particular study. It may be to improve the knowledge of vaccines or infectious diseases, or 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 54 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 55 of 84 to improve existing tests or develop new tests to assess vaccines. Human genetic tests will never 
be performed on these samples without specific individual informed consent. 
8 Clinical Supplies  
[COMPANY_011] Pasteur will supply the study sites with p rotocols, ICFs, CRBs , SAE reporting forms, diary 
cards, and other study documents, as well as with the following study materials: all study  
vaccines, blood collection tubes, cryotubes, cryotube storage boxes, cryotube labels, temperature 
recorders, shippi[INVESTIGATOR_35275], rulers, pregnancy tests, and digital thermometers.  
The me ans for performing EDC will be defined by [CONTACT_35346] . If a computer is provided by 
[CONTACT_35346] , it will be retrieved at the end of the study. 
The Investigator will supply all vaccination supplies, phlebotomy, and centrifugation equipment, including biohazard and/ or safety supplies. The biohazard and safety supplies include needles and 
syringes, examination gloves, laboratory coats, sharps disposal containers, and absorbent countertop paper. The site will ensure that all biohazard wastes are autoclaved and disposed of in accordance with local practices. The Investigator will also supply appropriate space in a temperature -monitored refrigerator for the storage of the products and for the blood samples, and 
appropriate space in a temperature -monitored fr eezer for serum aliquots.  
In the event that additional supplies are required, study staff must contact [CONTACT_35346] , 
indicating the quantity required. Contact [CONTACT_35347].  
9 Endpoints and Assessment Methods  
9.1 Primary Endpoints and Assessment Methods  
9.1.1 Safety 
There are no primary objectives for safety.  
9.1.2 Immunogenicity  
There are no primary objectives for immunogenicity. 
9.1.3 Efficacy 
No clinical efficacy data will be obtained in the study. 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 55 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 56 of 84 9.2 Secondary Endpoints and Assessment Methods 
9.2.1 Safety 
There are no secondary objectives for safety.  
9.2.2 Immunogenicity  
There are no secondary objectives for immunogenicity. 
9.2.3 Efficacy 
No clinical efficacy data will be obtained in the study. 
9.3 Observational Endpoints and Assessment Methods  
The observati onal safety objective is presented in  Section 2.1.1. 
9.3.1 Safety 
[IP_ADDRESS] Safety Definitions  
The following definitions are taken from the International Conference on Harmonisation ( ICH) 
E2A Guideline for Clinical Safety Data Management: Definitions and Stan dards for Expedited 
Reporting. 
Adverse Event (AE):  
An AE is any untoward medical occurrence in a patient or in a clinical investigation subject 
administered a medicinal product and which does not necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding, for example), symptom or disease temporally associated with the use 
of a medicinal product, whether or not considered related to the medicinal product.  
Therefore, an AE may be: 
• A new illness  
• The worsening of a pre- existing condition  
• An effect of the vaccination, including the comparator 
• A combination of the above 
All AEs include serious and non- serious AEs.  
Surgical procedures are not AEs; they are the actions taken to treat a medical condition. It is the 
condition leading to the action taken that is the AE (if it occurs during the study period). 
Pre-existing medical conditions are not to be reported as AEs. However, if a pre- existing medical 
condition worsens following study interventions in frequency or intensity, or if according to the 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 56 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 57 of 84 Investigator there is a change in its clinical significance, this change should be reported as an AE 
(exacerbation). This applies equally to recurring epi[INVESTIGATOR_35276]- existing conditions (e.g., asthma) 
if the frequency or intensity increases post -vaccination. 
Serious Adverse Event (SAE):  
Serious  and severe are not synonymous. The term severe is often used to describe the intensity of 
a specific event as corresponding to G rade 3. This is not the same as serious, which is based on 
subject/event outcome or action criteria usually associated with events that pose a threat to a 
subject’s life or functioning. Seriousness, not severity, serves as a guide for defining regulatory reporting obligations. 
An SAE is any untoward medical occurrence that at any dose  
• Results in death  
• Is life -threatening
a 
• Requires inpatient hospi[INVESTIGATOR_35277] 
• Results in persistent or significant disability/incapacityc 
• Is a congenital anomaly/birth defect  
• Is an important medical event (IME)  
Medical and scientific judgment should be exercised in deciding whether expedited reporting 
is appropriate in other situations, such as IMEs that may not be immediately life -threa tening 
or result in death or hospi[INVESTIGATOR_059] , but may jeopardize the health of the subject or may 
require intervention to prevent one of the other outcomes listed in the definition above. These IMEs should also usually be considered serious. Examples of such events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse, new- onset diabetes,  or autoimmune disease.  
Adverse Reaction:  
All noxious and unintended responses to a medicinal product related to any dose should be considered ARs. 
(The phrase “responses to a medicinal product” means that a causal relationship between a medicinal product and an AE is at least a reasonable possibility)  
                                                 
a  The term “life -threatening” refers to an event in which the subject  was at risk of death at the time of the event; it 
does not refer to an event which hypothetically might have caused death if it were more severe.  
b  All medical events leading to hospi[INVESTIGATOR_167480] , with the exception of: 
hospi[INVESTIGATOR_35280].  
c  “Persistent or significant disability or incapacity” means that there is a substantial disruption of a person’s ability 
to carry out normal life  functions.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 57 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 58 of 84 The following additional definitions are used by [CONTACT_35346]: 
Immediate Event/Reaction:  
Immediate events are recorded to capture medically relevant unsolicited systemic AEs (including 
those related to the product administered) that occur within the first 20 minutes after vaccination. 
Solicited Reaction:  
A solicited reaction is an “expected” AR (sign or symptom) observed and reported under the 
conditions (nature and onset) prelisted in the protocol and CRB (e.g., injection site pain from Day [ADDRESS_878728]-vaccination).  
By [CONTACT_108], solicited reactions are to be considered as being related to the product administered.  
For injectable vaccines, s olicited reactions can either be solicited injection site reactions or 
solicited systemic reactions.  
The assessment of these reactions by [CONTACT_167536]. 
Unsolicited AE /AR:  
An unsolicited AE is an observed AE that does not fulfill the conditions prelisted in the CRB in terms of diagnosis and/or onset window post-vaccination. For example, if headache between Day 0 and Day 7 is a solicited reaction (i.e., prelisted in the protocol and CRB), then a headache 
starting on D ay [ADDRESS_878729]-vaccination is 
an unsolicited AE. Unsolicited AEs includes both serious (SAEs) and non- serious unsolicited 
AEs.  
Injection Site Reaction:  
An injection site reaction is an AR at and around the injection site . Injection site reactions are 
commonly inflammatory reactions. They are considered to be related to the product administered. 
Systemic AE:  
Systemic AEs are all AEs that are not injection or administration site reactions. They therefore 
include systemic manifestations such as headache, fever, as well as localized or topi[INVESTIGATOR_29480] (e.g., erythema that is localized but that is not occurring at the injection site).  
Adverse Event of Special Interest (AESI):  
An AESI  is one of scientific and medical concern s specific to the Sponsor’s product or program, 
for which ongoing monitoring and rapid communication by [CONTACT_654769]. Such an event might warrant f urther investigation in order to characterize and 
understand it. Depending on the nature of the event, rapid communication by [CONTACT_29546] (e.g., regulators) might also be warranted. 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 58 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 59 of 84 [IP_ADDRESS] Safety Endpoints  
The observational endpoints for th e evaluation of safety are:  
1) Occurrence, nature (Medical Dictionary for Regulatory Activities [MedDRA] preferred 
term), duration, intensity, and relationship to vaccination of any unsolicited systemic AEs 
reported in the 20 minutes after vaccination. 
2) Occurr ence, time to onset, number of days of occurrence, intensity, action taken, and whether 
the reaction led to early termination from the study, of solicited injection site reactions (prelisted in the subject’s diary card and CRB)  occurring from Day 0 through Day 7 after 
vaccination. 
3) Occurrence, time to onset, number of days of occurrence, intensity, action taken, and whether the reaction led to early termination from the study, of solicited systemic reactions (prelisted in the subject’s diary card and CRB) oc curring from Day 0 through Day 7 after vaccination. 
4) Occurrence, nature (MedDRA preferred term), time to onset, duration, intensity, action taken, relationship to vaccination (for systemic AEs only), and whether the event led to early termination from the s tudy, of unsolicited AEs from Visit 1 through Visit 2 for subjects 
receiving 1 dose or from Visit 1 through Visit 3 for subjects receiving 2 doses. 
5) Occurrence, nature (MedDRA preferred term), time to onset, seriousness criteria, relationship to vaccination, outcome, and whether the SAE led to early termination from the study, of SAEs from Visit [ADDRESS_878730] will be captured as SAEs. These include new onset of GBS, 
encephalitis/myelitis (including transverse myelitis), neuritis (including Bell’s palsy, optic 
neuritis, and brachial neuritis), thrombocytopenia, vasculitis, convulsions (including febrile convulsions [children only]), and anaphylaxis or other hypersensitivity/allergic reactions from Visit 1 through Visit 2 for subjects receiving 1 dose of vaccine, or from Visit 1 through Visit 3 for 
subjects receiving 2 doses of vaccine.  
[IP_ADDRESS] Safety Assessment Methods 
At each visit , the Investigator or a delegate will perform a directed physical examination, if 
indicated, based on interim history and will ask the subject or subject’s parent/guardian about any 
solicited reactions and uns olicited AEs recorded in the diary card, as well as about any other AEs 
that may have occurred since the previous visit. All relevant data will be transcribed into the CRB according to the instructions provided by [CONTACT_1034]. 
[IP_ADDRESS].[ADDRESS_878731] -vaccination observation should be documented in the source document. Any AE 
that occurs during this period will be noted on the source document and recorded in the CRB, as 
follows: 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 59 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 60 of 84 • Unsolicited systemic AEs will be recorded as immediate AEs in the CRB (presence marked as 
“yes” and details collected).  
• Solicited and unsolicited injection site reactions and solicited systemic reactions will be recorded in the CRB in the same way as any reactions starting on the day of vaccination.  
• SAEs will be recorded in the CRB and reported to the Sponsor in the same way as any other SAEs, according to the procedures described in Section 10.  
[IP_ADDRESS].2 Reactogenicity (Solicited Reactions From  Day 0 Through Day 7 After Each 
Vaccination) 
After each vaccination, the subject or the subject’s parent/guardian will be provided with a diary 
card, a digital thermometer, and a flexible ruler, and will be instructed how to use them. The 
following items will be recorded by [CONTACT_29159]’s parent/guardian  in the diary card 
on the day of vaccination and for the next 7 days (i.e., D ay 0 through Day 7) until resolution: 
• Daily temperature, with the route by [CONTACT_35350]  
• Daily measurement or i ntensity grade of all other solicited injection site and systemic 
reactions  
• Action taken for each event (e.g., medication) 
The action(s) taken by [CONTACT_35323]’s parent/guardian to treat and/or manage any solicited reactions  will be classified in the CRB using the following list (all applicable items 
should be checked): 
• None 
• Medication  
• Health care provider contact  
• Hospi[INVESTIGATOR_057]  
• Discontinuation of study vaccination  
 
The subject or subject’s parent/guardian will be contact[CONTACT_5143] [ADDRESS_878732] is made. Every telephone attempt and its outcome will be documented in the source document. 
Table 9.1, Table 9.2, Table 9.3, Table 9.4, and Table 9.5 present the injection site reactions and 
systemic reactions that are prelisted in the diary cards and CRB, together with the intensity scales.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 60 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 61 of 84 Table 9.1: Solicited Injection Site Reactions: Terminology, Definitions, and Intensity Scales (Subjects 6 to < 36 Months of Age)  
CRB term  
(MedDRA lowest 
level term [LLT])  Injection site tenderness  Injection site erythema  Injection site swelling  
Data analysis term 
(MedDRA preferred 
term [PT])  Injection site pain Injection site erythema  Injection site swelling 
Diary card term  Tenderness  Redness  Swelling  
Definition  Pain when the injection site is touched or injected limb mobilized  Presence of a redness including the approximate point of needle entry Swelling at or near the injection site  
Swelling or edema is caused by a fluid 
infiltration in tissue or cavity and, depending 
on the space available for the fluid to disperse, swelling may be either soft (typi[INVESTIGATOR_897]) or fir m (less typi[INVESTIGATOR_2855]) to touch and 
thus can be best described by [CONTACT_654770] 1: Minor reaction when injection site is 
touched 
Grade 2: Cries or protests when injection site 
is touched  
Grade 3: Cries when injected  limb is 
mobilized, or the movement of the injected 
limb is reduced  Grade 1: > 0 to <  25 mm  
Grade 2: ≥ 25 to <  50 mm  
Grade 3: ≥ 50 mm Grade 1: > 0 to <  25 mm  
Grade 2: ≥ 25 to <  50 mm  
Grade 3: ≥ 50 mm 
a  For the subjective reaction of tenderness, parents/guardians will record the intensity level (Grade  1, 2, or 3) in the diary card. For the measurable reactions of redness and swelling, 
they will record just the size of the reaction, and the classification as Grade  1, 2, or 3 will be assigned at the  time of the statistical analysis.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 61 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 62 of 84 Table 9.2: Solicited Injection Site Reactions: Terminology, Definitions, and Intensity Scales (Subjects 3 to < 9 Years of Age) 
CRB term 
(MedDRA lowest 
level term [LLT])  Injection site pain  Injection site erythema  Injection site swelling  
Data analysis term 
(MedDRA preferred term [PT])  Injection site pain Injection site erythema  Injection site swelling 
Diary card term  Pain Redness  Swelling  
Definition  Pain either present  spontaneously or when 
the injection site is touched or injected limb 
is mobilized Presence of a redness including the 
approximate point of needle entry Swelling at or near the injection site  
Swelling or edema is caused by a fluid 
infiltration in tissue or  cavity and, depending 
on the space available for the fluid to 
disperse, swelling may be either soft (typi[INVESTIGATOR_897]) or firm (less typi[INVESTIGATOR_2855]) to touch and thus can be best described by [CONTACT_654770] 1: Easily tolerated  
Grade 2: Sufficiently discomforting to 
interfere with normal behavior or activities  
Grade 3: Incapacitating, unable to perform 
usual activities  Grade 1: > 0 to <  25 mm  
Grade 2: ≥ 25 to <  50 mm  
Grade 3: ≥ 50 mm Grade 1: > 0 to <  25 mm  
Grade 2: ≥ 25 to <  50 mm  
Grade 3: ≥ 50 mm 
a  For the subjective reaction of pain, subjects or subjects ’ parent s/guardian s will record the intensity level (Grade  1, 2, or 3) in the diary card. For the measurable reactions of redness 
and swelling, they will record just the size of the reaction, and the classification as Grade  1, 2, or 3 will be assigned at the time of the statistical analysis.  
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 62 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 63 of 84 Table 9.3: Solicited Injection Site Reactions: Terminology, Definitions, and Intensity Scales (Subjects 18 Years of Age and Older)  
CRB term 
(MedDRA lowest 
level term [LLT])  Injection site pain  Injection site erythema  Injection site swelling  
Data analysis term 
(MedDRA preferred term [PT])  Injection site pain Injection site erythema  Injection site swelling 
Diary card term  Pain Redness  Swelling  
Definition  Pain either present spontaneously or when the injection site is touched or injected limb 
is mobilized
 Presence of a redness including the 
approximate point of needle entry Swelling at or near the injection site  
Swelling or edema is caused by a fluid 
infiltration in tissue or cavity and, depending 
on the space available for the fluid to disperse, swelling may be either soft (typi[INVESTIGATOR_897]) or firm (less typi[INVESTIGATOR_2855]) to touch and thus can be best described by [CONTACT_654771]/Proprietary Information 
                
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 63 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 64 of 84 Intensity scalea 
 Grade 1: A type of adverse event that is 
usually transient and may require only 
minimal treatment or therapeutic intervention. The event does not generally 
interfere with usual activities of daily living.  
Grade 2: A type of adverse event that is 
usually alleviated with additional therapeutic 
intervention. The event interferes with usual activities of daily living, causing discomfort 
but poses no significant or permanent risk of 
harm to the research participant.  
Grade 3: A type of adverse event that 
interrupts usual activities of daily living, or 
significantly affects clinical status, or may 
require intensive therapeutic intervention.  Grade 1: ≥ 25 to ≤  50 mm  
Grade 2: ≥ 51 to ≤  100 mm  
Grade  3: > 100 mm Grade 1: ≥ 25 to ≤  50 mm  
Grade 2: ≥ 51 to ≤  100 mm  
Grade 3: > [ADDRESS_878733] the intensity level (Grade  1, 2, or 3) in the diary card. For the measurable reactions of redness and swelling, they will record 
just the size of the reaction, and the classification as Grade  1, 2, or 3 will be assigned at the time of the statistical analysis  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 64 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 65 of 84 Table 9.4: Solicited Systemic Reactions: Terminology, Definitions, and Intensity Scales (Subjects  6 to < 36 Months of Age) 
CRB term (MedDRA 
lowest level term 
[LLT]) Fever 
 Vomiting  Crying abn ormal  Drowsiness  Appetite lost  Irritability  
Data analysis term 
(MedDRA preferred 
term [PT])  Pyrexia  Vomiting  Crying  Somnolence  Decreased appetite  Irritability  
Diary card term  Temperature  Vomiting  Abnormal crying  Drowsiness  Loss of appetite  Irritability  
Definition  Elevation of 
temperature to  
≥ 38.0° C (≥ 100.4°F)  Vomiting does not 
include spi[INVESTIGATOR_35281] a determined 
reason  Reduced interest in 
surroundings, or increased sleepi[INVESTIGATOR_35282]: increased 
fussiness, whining, and 
fretfulness despi[INVESTIGATOR_654745]  1:  
≥ 38.0° C to ≤  38.5°C  
or ≥ 100.4°F to ≤  101.3°F  Grade  1: 1 epi[INVESTIGATOR_35267] 
24 hours  Grade  1: < 1 hour Grade  1: Sleepi[INVESTIGATOR_654746]  1: Eating less 
than normal Grade  1: Easily 
consolable  
 Grade  2: 
> 38.5°C to ≤  39.5°C  
or > 101.3°F to ≤ 103.1°F  Grade  2: 2–5 epi[INVESTIGATOR_11644] 24  hours  Grade  2: 1–3 hours  Grade  2: Not interested in 
surroundings or did not wake up for a feed/meal  Grade  2: Missed 1 or 2 
feeds/meals completely  Grade  2: Requiring 
increased attention  
 Grade  3: > 39.5°C  
or > 103.1°F  Grade  3: ≥ 6 epi[INVESTIGATOR_11644] 24  hours or 
requiring parenteral hydration Grade  3: > 3 hours  Grade  3: Sleepi[INVESTIGATOR_654747]  3: Refuses 
≥ 3 feeds/meals or 
refuses most feeds/meals  Grade  3: Inconsolable  
a  For all reactions but fever, parents/guardians will record the intensity level (Grade  1, 2, or 3) in the diary card. For fever, they will record the body temperature, and the 
classification as Grade  1, 2, or 3 will be assigned at the time of the statistical analysis based on the unit used to measure the temperatur e and the intensity scale.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 65 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 66 of 84 Table 9.5: Solicited Systemic Reactions: Terminology, Definitions, and Intensity Scales (Subjects  3 to < 9 Years of Age and 18 Years of Age  
and Older)  
CRB term 
(MedDRA lowest 
level term [LLT])  Fever 
 Headache  Malaise Myalgia 
Data analysis term 
(MedDRA preferred term [PT])  Pyrexia  Headache  Malaise  Myalgia  
Diary card term  Temperature  Headache  Feeling unwell  Muscle aches and pains  
Definition  Elevation of temperature to  
≥ 38.0°C (≥ 100.4°F)  Pain or discomfort in the head or 
scalp. Does not include migraine.  General ill feeling.  
Malaise is a generalized feeling of 
discomfort, illness, or lack of well-being that can be associated with a 
disease state. It can be accompanied 
by a sensation of exhaustion or 
inadequate energy to accomplish 
usual activities.  Muscle aches and pains are common 
and can involve more than one muscle at the same time. Muscle 
pain can also involve the soft tissues that surround muscles. These 
structures, whi ch are often referred 
to as connective tissues, include 
ligaments, tendons, and fascia (thick 
bands of tendons).  
Does not apply to muscle pain at the 
injection site which should be reported as injection site pain.  
Intensity scalea Grade  1: ≥ 38.0°C to ≤  38.4°C,  
or ≥ 100.4°F to ≤  101.1°F  Grade  1: A type of adverse event 
that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event 
does not generally interfere with usual activities of daily living.  Grade  1: A type of  adverse event 
that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event 
does not generally interfere with usual activities of daily living.  Grade  1: A type of adverse event 
that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual activities of daily living.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 66 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 67 of 84  Grade  2: ≥ 38.5°C to ≤  38.9°C,  
or ≥ 101.2°F to ≤  102.0°F  Grade  2: A type of adverse event 
that is usually alleviated w ith 
additional therapeutic intervention. 
The event interferes with usual 
activities of daily living, causing discomfort but poses no significant 
or permanent risk of harm to the 
research participant.  Grade  2: A type of adverse event 
that is usually alleviated with additional therapeutic intervention. 
The event interferes with usual 
activities of daily living, causing discomfort but poses no significant 
or permanent risk of harm to the 
research participant.  Grade  2: A type of adverse event 
that is usu ally alleviated with 
additional therapeutic intervention. 
The event interferes with usual 
activities of daily living, causing discomfort but poses no significant 
or permanent risk of harm to the 
research participant.  
 Grade  3: ≥ 39.0°C  
or ≥ 102.1°F  Grade  3: A type of adverse event 
that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require 
intensive therapeutic intervention.  Grade  3: A type of adverse event 
that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.  Grade  3: A type of adverse event 
that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require 
intensive therapeutic inte rvention.
 
a  For all reactions but fever, subjects or subjects ’ parents/guardians will record the intensity level (Grade  1, 2, or 3) in the diary card. For fever, they will record the body 
temperature, and the classification as Grade  1, 2, or 3 will be assigned at the time of the statistical analysis based on the unit used to measure the temperature and the intensity scale.  
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 67 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 68 of 84 Important notes for the accurate assessment of temperature:  
Subjects or subjects’  parents/guardians are to measure body temperature once per day, preferably 
always at the same time. The optimal time for measurement is the evening, when body 
temperature is the highest. Temperature is also to be measured at the time of any apparent fever. The observed dail y temperature and the route of measurement are to be recorded in the diary card , 
and the highest temperature will be recorded by [CONTACT_35358]. The preferred route for this study is rectal for subjects 6 to < 36 months of age, and oral for subjects 3 to < 9 years of age and ≥ [ADDRESS_878734] not be used. 
[IP_ADDRESS].3 Unsolicited Adverse Events  
In addition to recording solicited reactions, subjects or subjects’ p arents /guardians will be 
instructed to record any other medical events that may occur from Visit 1 through Visit 2 (Diary 
Card 1) for al l subjects and from Visit 2 through Visit 3 (Diary Card 2) for subjects receiving 
[ADDRESS_878735] for this purpose.  
Information on SAEs will be collected and assessed throughout the study, from Visit 1 through 
Visit 2 for subjects receiving 1 dose of study vaccine, and from Visit 1 through Visit 3 for subjects receiving 2 doses of study vaccine.  
Any SAE occurring at any time during the study will be reported by [CONTACT_654772]; this includes checking the “Serious” box on the AE CRF and completing the appropriate Death/Safety Complementary Information CRFs. All information concerning the SAE is to be reported either as part of the initial reporting or during follow- up reporting if relevant information became available later 
(e.g., outcome, medical history, results of investigations, copy of hospi[INVESTIGATOR_35286]). See Section  10 for further details on SAE reporting. 
For each unsolicited AE (whether serious or non-serious), the following information is to be recorded:  
• Start and stop dates
a  
• Intensity of the event: 
For measurable unsolicited AEs that are part of the list of solicited reactions, the size of the 
AE as well as the temperature for fever will be collected and analyzed based on the corresponding scale used for solicited reactions (see Table 9.1, Table 9.2, Table 9.3, Table 
9.4, and Table 9.5).  
                                                 
a  The stop date of all related AEs will be actively solicited. For other events, the Investigator will provide the stop 
date when it becomes available. AEs for which no stop date was obtained during the course of the study will be 
considered a s ongoing at the end of the study.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 68 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 69 of 84 All other unsolicited AEs will be classified according to the f ollowing intensity scale: 
• Grade  1: A type of AE  that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual activities of 
daily living.  
• Grade  2: A type of AE  that is usuall y alleviated with additional therapeutic intervention. 
The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant.  
• Grade  3: A type of AE  that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.  
• Whether the AE was related to the investigational product (for unsolicited systemic AEs) 
The Investigator will assess the causal rel ationship between the AE and the investigational 
product as either “Not related” or “Related”, as described in  Section [IP_ADDRESS].5. 
• Action taken for each AE (e.g., medication) 
The action(s) taken by [CONTACT_35323] ’s parent(s)/guardian(s) to treat and/or manage 
any unsolicited AEs will be classified in the CRB usi ng the following list (all applicable items 
should be checked): 
• None 
• Medication  
• Health care provider contact  
• Hospi[INVESTIGATOR_057]  
• Discontinuation of study vaccination 
• Whether the AE was serious 
For each SAE, the I nvestigator will complete all seriousness criteria that apply (outcome, 
elapsed time, and relationship to study procedures) 
• Whether the AE caused study discontinuation 
[IP_ADDRESS].[ADDRESS_878736] will be captured as SAEs. These include new onset of GBS, 
encephaliti s/myelitis (including transverse myelitis), neuritis (including Bell’s palsy, optic 
neuritis, and brachial neuritis), thrombocytopenia, vasculitis, convulsions (including febrile convulsions [children only]), and anaphylaxis or other hypersensitivity/aller gic reactions from 
Visit 1 through Visit 2 for subjects receiving 1 dose of vaccine, or from Visit 1 through Visit 3 for subjects receiving 2 doses of vaccine. 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 69 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 70 of 84 [IP_ADDRESS].[ADDRESS_878737] administered as either not related  or related , based on the following definitions: 
Not related – The AE is clearly/most probably caused by [CONTACT_29549], therapeutic intervention, or concomitant therapy; or the delay 
between vaccination and the onset of the AE is incompatible with a causal relationship; or the AE started before the first vaccination (screening phase, if applicable)  
Related  – There is a “reasonable possibility” that the AE  was caused by [CONTACT_35361], meaning that there is evidence or arguments to suggest a causal relationship 
Note: By [CONTACT_559], all AEs reported at the injection site (whether solicited or unsolicited) and all solicited systemic AEs are consider ed to be related to the administered product and, therefore , 
are referred to as reactions and do not require the Investigator’s opi[INVESTIGATOR_125611]. 
Adverse events likely to be related to the product, whether serious or not, that persist at the end of 
the study will be followed up by [CONTACT_125630]’s condition. The Investigator will inform the Sponsor of the date of final disappearance of the event or the date of “chronicity” establ ishment. 
9.3.2 Immunogenicity  
The observational immunogenicity objective is presented in Section 2.1.2. 
[IP_ADDRESS] Immunogenicity Endpoints  
Immunogenicity will be evaluated in all subjects by [CONTACT_654773] 0 (Visit 1) and after final vaccination (28 [window, 28–35] days post-final vaccination for 
subjects 6 months to < 9 years of age [Visit 2 for subjects receiving 1 dose; Visit 3 for subjects 
receiving 2 doses]; or 21 [window, 21–28] days post- vaccination for subjects ≥ 18 years of age) 
using the HAI assay technique.  
For each influenza vaccine strain (i.e., 3 strains for Fluzone High- Dose vaccine [a trivalent 
vaccine] and 4 strains for Fluzone Quadrivalent vaccine and Flublok Quadrivalent vaccine), HAI 
assay titers at pre- vaccination (Day 0) and after the final vaccination will be determined in 
duplicate.  
The derived endpoints
a are: 
• Geometric means of HAI assay titers at pre-vaccination and post- final vaccination  
• Ratios of post-final vaccination titers divided by [CONTACT_094]-vaccination titers 
• Seroprotection: a titer ≥ 40 (l/dilution [dil]) at pre -vaccination and at post- final vaccination  
• Seroconversion: either a pre- vaccination titer <  10 (1/dil) and a post- final vaccination titer 
≥ 40 (1/dil), or a pre -vaccination titer ≥ 10 (1/dil) and a ≥ 4-fold increase in post- final 
vaccination titer  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 70 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878738]- final vaccination in each of the derived  endpoints is defined as 28 (window, 28 –35) days post -final  
  vaccination for subjects 6 months to <  9 years of age, and 21 (window, 21– 28) days post -vaccination for subjects 
  ≥ 18 years  of age 
[IP_ADDRESS] Immunogenicity Assessment Methods  
Anti-influenza antibodies will be measured by [CONTACT_654774]’s GCI 
department or an external testing laboratory under GCI’s supervision. Serum samples and quality 
control sera (sheep and/or human sera) will be incubated with Sigma Type III NA to eliminate non-specific inhibitors. Adsorption of spontaneous anti- species agglutinins will be performed by 
[CONTACT_654775] a red blood cell (RBC) suspension. Following this, the mixtures will be centrifuged and the supernatan ts containing the treated sera 
will be collected for testing. Ten 2 -fold dilutions (starting at 1/10) of the treated serum samples 
and quality control sera will be incubated with a previously titrated influenza virus at a concentration of 4 hemagglutination unit/[ADDRESS_878739] serum dilution in which complete inhibition of hemagglutination occurred. 
Each serum sample will be titrated in independent duplicates, and the 2 values, which do not differ by [CONTACT_190635] 2-fold dilution, will be reported. The geometric mean titer between the 2 values will be calculated after the release of the data to the Clinical Data Management (CDM) platform. The lower limit of quantification (LLOQ) for HAI is set at 10, the lowest serum dilution used in the assay (i.e., 1/10). Titers below thi s level are reported as < 10. If the highest/last serum 
dilution used in the assay exhibits complete inhibition of hemagglutination, the serum antibody titer will be reported as ≥ [ZIP_CODE] (1/dil). 
9.3.3 Efficacy 
No clinical efficacy will be obtained in the study. 
9.3.4 Serum Collection  
The observational objective for serum collection is presented in  Section 2.1.3. 
[IP_ADDRESS] Serum Collection Endpoints and Assessment Methods  
There are no observational endpoints for the serum collection objective.  
[ADDRESS_878740] 
document all SAEs regardless of causal relationship, and notify the Sponsor and the Clinical Research Associate ( CRA) within the notification timelines stated in the following sections. The 
Investigator will give access and provide the Sponsor and the CRA with all necessary information to allow the Sponsor to conduct a detailed analysis of the safety of the investigational product(s). It is the responsibility of the Investigator to request a ll necessary documentation (e.g., medical 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 71 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 72 of 84 records, discharge summary, autopsy report) in order to provide comprehensive safety 
information. All relevant information must then be transcribed onto the AE CRF and the 
appropriate Death/Safety Complementary Inf ormation CRFs. 
10.[ADDRESS_878741]’s participation in the study or experiment must 
be reported within 24 hours to the Sponsor’s GP E Department and to the CRA. Every SAE must 
be reported, even if the Investigator considers that it is not related to the vaccine. The Investigator 
(licensed physician [MD or DO]) must validate the information entered on the AE CRF by [CONTACT_167543]. 
The Investigator must indicate on the AE CRF that the event was serious and must complete the 
relevant SAE section of this form as well as the appropriate Death/Safety Complementary Information CRFs. An e -mail alert will automatically be sent by [CONTACT_654776], the CRA, and the RMOs  with relevant SAE information details.  
If the EDC system is unavailable, the site must notify the Sponsor, using the paper version of the CRB, as described in the Operating Guidelines: 
The Investigator must complete the paper copi[INVESTIGATOR_35289]/Safety Complementary Information CRFs and send them to the Sponsor by 1 of  the 
following means: 
• By [CONTACT_6791], to the following number:  
• In PDF format to the following e-mail address, using a method of transmission that 
includes password protection:  
• By [CONTACT_29554], to the following address:  Reception & Triage – Case Management  
Global Pharmacovigilance Department, [COMPANY_011] Pasteur, Inc. 
Discovery Drive, Swiftwater, PA [ADDRESS_878742] be updated within 24 hours after the Investigator has become aware of any new relevant information concerning the SAE (e.g., outcome, precise description of medical history, res ults of the investigation). All relevant information must be 
included directly in the AE CRF and the appropriate Death/Safety Complementary Information CRFs . An e- mail alert will be sent automatically to the GP E Department and to the CRA. Copi[INVESTIGATOR_35290] (e.g., medical records, discharge summary, autopsy) may be requested by [CONTACT_654777].  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 72 of 85

[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878743](s), other products (e.g., a benefit vaccine), or to the experiment must also 
be reported as soon as possible. In such a case, the reporti ng procedure to be followed is identical 
to that described in Section 10.1. 
10.[ADDRESS_878744] administered will be evaluated by [CONTACT_35370] [IP_ADDRESS].5. 
Following this, the Sponsor’s Pharmacovigilance Global Safety Expert will also assess the causal relationship to the product, based on the available information and current medical knowledge. 
The causal relationship to study procedures will be also assessed in the CRB.  
The decision to modify or discontinue the study may be made after mutual agreement between the 
Sponsor and the Investigator( s). 
10.5 Reporting SAEs to Health Authorities and IECs /IRBs 
The Sponsor will inform the relevant health authorities of any reportable SAEs according to the 
local regulatory requirements. Reporting to the health authorities will be according to the Sponsor’s standard operating procedures. 
The Sponsor’s RMOs  will notify the Investigators in writing of the occurrence of any reportable 
SAEs. The Investigators/Sponsor will be responsible for informing the IRB(s) that reviewed the 
study protocol. 
11 Data Collection and Management 
11.1 Data Collection and CRB Completion 
Individual diary cards, specifically designed for this study by [CONTACT_654778], will be given to study participants for the recording of daily safety information as 
described in  Section [IP_ADDRESS].  These diary cards will include prelisted terms and intensity scales 
(see Table 9.1 , Table 9.2 , Table 9.3, Table 9.4, and Table 9.5 ) as well as areas for free text to 
capture additional safety information or other relevant details. Subjects or subjects’ 
parents/guardians will also be provided with rulers for measuring the size of injection site reactions, and with standard digital thermometers for measuring daily temperatures. To ensure consistency of reporting, the study sites will instruct subjects or subjects’ parents/guardians on 
how to correctly use these tools.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 73 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 74 of 84 At specified intervals, the Investigator or an authorized designee will interview the subjects or 
subjects’ parents/guardians to collect the information recorded in the diary card, and will attempt 
to clarify anything that is incomplete or unclear. All clinical study information gathered by [CONTACT_654779] a web-based CRB. (Any information that was not documented in the diary card will first be captured in 
the source document and then reported electronically.) The CRB has been designed specifically 
for this study  under the responsibility of the Sponsor, using a validated Electronic 
Records/Electronic Signature -compliant platform (21 CFR Part 11).  
To ensure the correct and consistent completion of the CRBs, the Sponsor or authorized 
representative will provide all necessary tools, instructions, and training to all site staff involved in data entry prior to study  start. Additional instructional documents such as training manuals and 
completion instructions will be provided to assist with data entry during the course of the study. 
Upon completion of training, each user requiring access to the EDC system will be issued a 
unique username [CONTACT_2383]. In the event of a change in study personnel, each newly assi gned 
individual will receive a unique username [CONTACT_2383]; the username [CONTACT_35395] a previous user may not be reissued. If any study personnel leave the study, the Investigator is 
responsible for informing the Sponsor immediately so that their access is deactivated. An audit trail will be initiated in the EDC system at the time of the first data entry to track all modifications and ensure database integrity. 
The Investigator is responsible for the timeliness, completeness, and accuracy of the information 
in the CRBs ; must provide explanations for all missing information; and must sign the CRB using 
an e- signature.  
11.2 Data Management  
Management of SAE and Pregnancy Data  
During the study, SAE data (reported on the AE, Death , and Safety Complementary Information 
CRFs ) and pregnancy data (reported by [CONTACT_35374]) will be integrated 
into the Sponsor’s centralized GP E database upon receipt of these forms and after a duplicate 
check. Each case will be assigned a case identification number. Each case will be assessed by [CONTACT_35375]. The a ssessment of related cases wi ll be done in collaboration with the 
Pharmacovigilance Global Safety Expert and the RMO (s). Follow-up information concerning a 
completed case will be entered into the GPE database, and a new version of the case will be 
created.  
The information from  the GP E database cases will be reconciled with that in the clinical database.  
Management of Clinical and Laboratory Data  
Clinical data, defined as all data reported in the CRB, and laboratory data will be handled by [CONTACT_1034]’s CDM  platform or authorized repres entative.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 74 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 75 of 84 During the study, clinical data reported in the CRBs will be integrated into the clinical database 
under the responsibility of the [COMPANY_011] Pasteur CDM platform. Data monitoring at the sites and 
quality control in the form of computerized logic and/or consistency checks will be systematically applied to detect errors or omissions. In addition, data reviews may be performed several times by [CONTACT_1034]’s staff in the course of the study. Any questions pertaining to the reported clinical data will be submitted to the Investigator for resolution using the EDC system. Each step of this 
process will be monitored through the implementation of individual passwords to maintain appropriate database access and to ensure database integrity.  
The validation of the immunogenicity data will be performed at the laboratory level following the 
laboratory’s procedures. Information from the laboratory will be checked for consistency before integration into the clinical data warehouse.  
After integration of all corrections  in the complete set of data, and after the SAE information 
available from CDM and the GP E Department has been reconciled, the database will be released for 
statistical analysis.  
11.3 Data Review  
A review of the data is anticipated through the data review proce ss led by [CONTACT_654780].   
12 Statistical Methods and Determination of Sample Size  
12.1 Statistical Methods  
Summaries of baseline demographic characteristics of the study subjects will be presented. The number of subjects enrolled and their age at enrollment (mean, median, and minimum and maximum), sex, race, and ethnic origin will be summarized, along with the number and description of protocol deviations. 
12.1.1 Hypotheses and Statistical Methods for Primary Objectives  
There are no primary objectives for this study. 
12.1.2 Hypotheses and Statistical Methods for Secondary Objectives  
There are no secondary objectives for this study. 
12.1.3 Statistical Meth ods for Observational Objectives 
For the main safety and immunogenicity parameters, 95% CIs of point estimates of proportions 
will be calculated using the normal approximation for quantitative data and the exact binomial 
distribution (Clopper -Pearson method) for proportions.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 75 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 76 of 84 [IP_ADDRESS] Safety  
All analyses will be descriptive; no hypotheses will be tested.  
[IP_ADDRESS] Immunogeni city 
All analyses will be descriptive; no hypotheses will be tested. Data will be summarized and 
presented for each age group.  
The following immunogenicity parametersa will be calculated for each influenza strain with 
95% CIs:  
• Geometric mean HAI assay titers at pre-vaccination and post- final vaccination  
• Geometric means of titer ratios (post-final vaccination divided by [CONTACT_094]- vaccination).  
• Seroprotection rates: The percentages of subjects with a titer ≥ 40 (l/dil) at pre -vaccination and 
at post- final vaccina tion  
• Seroconversion rates: The percentages of subjects with either a pre- vaccination titer 
< 10 (1/dil) and a post- final vaccination titer ≥ 40 (1/dil), or a pre -vaccination titer ≥ 10 (1/dil) 
and a ≥ 4-fold increase in post- final vaccination titer  
a  Post-final vaccination in each of the immunogenicity parameters is defined as 28 (window, 28 –35) days post -final 
vaccination for subjects 6  months to < 9 years of age, and 21 (window, 21 –28) days post -vaccination for subjects 
≥ 18 years of age.  
12.2 Analysis Sets  
Three main analysis sets will be used: the Safety Analysis Set, the Full Analysis Set (FAS), and 
the Per -Protocol Analysis Set (PPAS).  
12.2.[ADDRESS_878745] their safety analyzed after “any dose” according to the vaccine 
they actually received as the first dose . Safety analysis after each dose will be assessed in the 
subset of the Safety Analysis Set having received that dose. All subjects will have their safety data 
analyzed after each vaccination according to the vaccine they actually received for that dose. 
Safety data recorded for a vaccine received out of the protocol design will be excluded from the analysis (and listed separately).  
12.2.[ADDRESS_878746] 1 strain.   
                                                 
a  for which safety data are scheduled to be collected  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 76 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878747] 1 of the following relevant 
protocol deviations will be excluded from the PP AS: 
• Subject did not meet all protocol-specified inclusion criteria or met at least 1 of the protocol-
specified exclusi on criteria  
• Subject did not complete the vaccination schedule  
• Subject received a vaccine or dose other than the one that he/ she was assigned to receive  
• Preparation and/or administration of vaccine was not done as per- protocol   
• Subject did not receive vacci ne in the proper time window  
• Subject did not provide a post- dose serology sample in the proper time window or a post-dose 
serology sample was not drawn 
• Subject received a protocol -prohibited therapy/medication/vaccine that might impact antibody 
response t o the study vaccine 
• Any other deviation identified during conduct of the study and judged by [CONTACT_654781] a potential impact on the assessment of immunogenicity 
In addition to the reasons listed above, subjects will also be excluded from the PPAS if their 
post-vaccination se rology sample did not produce a valid test result for any antigen. 
12.2.4 Populations Used in Analyses  
Baseline and demographic analyses will be performed on all enrolled subjects.  
The safety analyses will be performed on the Safety Analysis Set.  
The immunogenicity analyses will be performed on both the FAS and PPAS. 
12.3 Handling of Missing Data and Outliers  
12.3.1 Safety 
No imputation of missing data will be conducted. All subjects with safet y data and all safety data 
recorded in the CRFs will be included in the safety analyses. No search for outliers will be 
performed. 
12.3.2 Immunogenicity  
For the computations, LLOQ and upper limit of quantification (ULOQ) will be managed as 
follows:  
• If a titer is  < LLOQ, then LLOQ/2 will be used 
• If a titer is ≥ LLOQ and < ULOQ, then the titer itself will be used 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 77 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 78 of 84 • If a titer is ≥ ULOQ, then ULOQ will be used 
Missing data will not be imputed. No search for outliers will be performed. 
12.4 Interim/Preliminary  Analysis 
No interim analyses are planned.   
12.5 Determination of Sample Size and Power Calculation  
The study will enroll approximately 240 subjects: approximately 30 subjects 6 to < 36 months of 
age will be administered Fluzone Quadrivalent vaccine (Group  1), approximately 30 subjects 
3 to < 9 years of age will be administered Fluzone Quadrivalent vaccine (Group 2), approximately 
60 subjects 18 to < 65 years of age will be administered Fluzone Quadrivalent vaccine (Group 3), approximately 60 subjects 18 to < 65 years of age will be administered Flu blok Quadrivalent 
vaccine (Group 4), and approximately 60 subjects ≥ 65 years of age will be administered Fl uzone 
High -Dose vaccine (Group 5).  
No study power assessment will be done for this study. Only descriptive statistical ana lyses will 
be conducted in this study. 
13 Ethical and Legal Issues and Investigator/ Sponsor Responsibilities  
13.[ADDRESS_878748] of the Study/ Good Clinical Practice  
The conduct of this study  will be consistent with the standards established by [CONTACT_35378] /or national 
regulations and directives.  
13.2 Source Data and Source Documents  
“Source data” are the data contained in source documents. Source documents are original documents or certified copi[INVESTIGATOR_014], and include, but are not limited to, diary cards, medical and hospi[INVESTIGATOR_1097], screening logs, informed consent/ assent forms, telephone contact [CONTACT_29543], and 
worksheets. The purpose of study source documents is to document the existence of subjects and to substantiate the integrity of the study  data collected. Investigators must maintain source 
documents so that they are accurate, complete, legible, and up to date. 
For missing or discrepant data on a diary card, the study coordinator will obtain verbal clarification  
from the subject, enter the response into the “ Investigator’s C omment ” page of the diary card, and 
transfer the information to the CRB. The subject pre -screening  log should list all individuals contact[CONTACT_35379], regardless of the outcome.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 78 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878749] to be re -printed, dated (with an indication of the date of 
change), and signed. Such records must also be kept together with the original printed copy. 
Good Documentation Practice should be followed by [CONTACT_167549].  
13.[ADDRESS_878750] Records  
Prior to initiation of the study, the Investigator will sign a fully executed confidentiality 
agreement with [COMPANY_011] Pasteur . 
[COMPANY_011] Pasteur personnel (or designates), the IRB(s), and regulatory agencies, including the FDA, require direct access to all study records, and will treat these documents in a confidential manner. 
In the event a subject’s medical records are not at the investigational site, it is the responsibility of the Investigator to obtain those records if needed. 
13.4 Monitoring, Auditing, and Archiving  
13.4.1 Monitoring   
Before the start of the study  (i.e., before the inclusion of the first subject in the first center),  the 
Investigators and the Sp onsor’s staff or a representative will meet at the site -initiation visit to 
discuss the study protocol and the detailed study procedures. Emphasis will be placed on inclusion 
and exclusion criteria, visit timing, safety procedures, informed consent procedures, SAE reporting procedures, CRB  completion, and the handling of samples and products. The Sponsor’s 
staff or a representativ e will ensure and document that all material to be used during the study has 
been received at the site; and that the study investigator team and local Sponsor /delegate  staff 
have been properly informed about the study, GCP and regulatory requirements, and the Sponsor’s procedures. Specific training sessions for the study investigator team and the CRAs on 
these topi[INVESTIGATOR_35291], and should be documented.  
The following instruction manuals will be provided: the CRB Completion Instructions  for 
entering data into the CRB, and the Operating Guidelines for detailed study  procedures such as 
the product management and sample-handling procedures. 
                                                 
a  Unless the electronic medical records are managed by [CONTACT_35385] 
21 CFR Part 11, in which case they are acceptable on  their own.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 79 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 80 of 84 After the start of the study , the Sponsor’s staff or a representative will be in regular contact [CONTACT_35386]-up visits. The Investigator or 
delegate must be available for these visits, and must allow the Sponsor /delegate st aff direct access 
to subject medical files and CRBs . During these visits, the Sponsor/delegate staff will:  
• Evaluate the quality of the study progress (adherence to protocol and any study- specific 
guidelines, quality of data collection and document completion, signature [CONTACT_35396], occurrence of SAEs, sample and product management, cold-chain monitoring, archiving) 
• Source-verify completed CRBs and any corresponding answered queries 
• Determine the number of complete or ongoing issues identified at monitoring visits (e.g., 
protocol deviations , SAEs) . Any identified problems will be discussed with the Investigator, 
and corrective or preventive actions will be determined, as appropriate. 
• After all protocol procedures have been completed and the data have been entered into the 
CRB, the Investigator must still be available to answer any queries forwarded by [CONTACT_1034]. 
All data -related queries must be completed prior to database lock.  
At the end of the study, a close -out visit will be performed to ensure th at: 
• The center has all the documents necessary for archiving  
• All samples have been shipped to the appropriate laboratories 
• All unused materials and products have been either destroyed or returned to the Sponsor 
13.4.2 Audits and Inspections  
A quality assurance au dit may be performed at any time by [CONTACT_1034]’s Clinical Quality 
Assessment  department or by [CONTACT_654782], GCP and ICH requirements, and other applicable regulations. An inspection may be conducted by [CONTACT_12721]. The Investigator must allow direct access to study documents during these inspections and audits. 
13.4.[ADDRESS_878751] keep all study documents after the completion or discontinuation of the 
study, whatever the nature of the investigational center (private practice, hospi[INVESTIGATOR_307], or institution), 
for as long as required by [CONTACT_774]. In the absence of any applicable laws or regulations, study documents will be kept at a minimum fo r the duration indicated on the 
Clinical Trial Agreement (CTA). In no event, should study personnel destroy or permit the destruction of any study documents upon less than 90 days advance written notification to the Sponsor. In addition, study  documents sh ould continue to be stored, at Sponsor’ s sole expense, in 
the event that the Sponsor requests in writing that such storage continues for a period of time that exceeds that required by [CONTACT_35388] . The Investigator will 
inform [COMPANY_011] Pasteur of any address change or if they will no longer be able to house the study documents. 
Archived data may be held on electronic records, provided that a back-up exists and that a hard 
copy can be obtained if required. The protocol, documentation, approvals, and all other 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 80 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 81 of 84 documents related to the study will be kept by [CONTACT_35389] (TMF). Data 
on AEs are included in the TMF.  All data and documents will be made available if requested by 
[CONTACT_190660].  
13.[ADDRESS_878752] and Insurance Coverage  
A CTA will be signed by [CONTACT_35391]’s performanc e, if relevant. The 
Sponsor has an insurance policy to cover any liabilities that may arise from use of the product 
and/or the study protocol. 
13.[ADDRESS_878753] 90  days prior to submission for publication/presentation. 
Any information identified by [CONTACT_125640], 
it being understood that the results of this study are not to be considered confidential.  
[COMPANY_011] Pasteur’s review can be expedited to meet publication guidelines. 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 81 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878754]  
 
1 Fiore AE, Bridges CB, Katz JM, Cox NJ. Inactivated influenza vaccines. In: Plotkin SA, 
Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Edinburgh, [LOCATION_006]: Elsevier/Saunders; 
2012;257- 93. 
2 Treanor JT. Influenza viruses, including avian influenza and swine inf luenza. In: Mandell 
GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. [LOCATION_001], NY: Churchill Livingstone; 2010:2265-88. 
3 Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and Control of Seasonal 
Influenza with Vaccines. Recommendations of the Advisory Committee on Immunization Practices - [LOCATION_002], 2016-17 Influenza Season. MMWR Recomm Rep. 2016;65(No. 
RR-5):[ADDRESS_878755] seasonal influenza. Vaccine. 2010;28(suppl 4):D45- 53. 
[ADDRESS_878756] century: optimizing 
protection of older adults. Vaccine. 2009;27(37):5043-53. 
6 Thompson WW, Shay DK, We intraub E, et al. Influenza- associated hospi[INVESTIGATOR_654748]. JAMA. 2004;292(11):1333-40. 
7 Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza-[LOCATION_002], 1976-2007. MMWR. 2010;59(33):1057-62. 
[ADDRESS_878757]. 2004;37(2):95-8. 
[ADDRESS_878758] Dis. 
2007;11(1):40-7. 
10 Glezen WP, Couch RB, Taber LH, et al. Epi[INVESTIGATOR_654749] B virus 
infections in Houston, [LOCATION_007], 1976- 1977. Am J Epi[INVESTIGATOR_5541]. 1980;111(1):13-22. 
11 Centers for Disease Control and Prevention. Prevention and control of seasonal influenza 
with vaccines: Recommendations of the Advisory Commit tee on Immunization Practices-
[LOCATION_002], 2013- 14. MMWR. 2013;62(RR07):1-43. 
[ADDRESS_878759] Dis J. 2014;33(6):630-6. 
13 Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety 
and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013;31(5):770-6. 
[ADDRESS_878760] on antibody responses in elderly persons. Arch Intern Med. 2006;166(10):1121-7. 
15 Couch RB, Winokur P, Brady R, et al. Safety and immunogenicity of a high dosage 
trivalent influenza vaccine among elderly subjects. Vaccine. 2007;25(44):7656-63. 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 82 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page [ADDRESS_878761] Dis. 2009;200(2):172- 80. 
[ADDRESS_878762] -
dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635- 45. 
18 Centers for Disease Control and Prevention. Prevention and control of influenza: 
recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR. 2007;56(RR- 6):1-54. 
[ADDRESS_878763] Dis J. 2005;24(10):925-7. 
20 Centers for Disease Control and Prevention. Epi[INVESTIGATOR_167492]-
Preventable Diseases. Hamborsky J, Kroger A, Wolfe S, eds. 13th ed. Washington D.C. Public Health Foundation, 2015. 
21 Woo EJ. Allergic reactions after egg -free recombinant influenza vaccine: reports to the US 
Vaccine Adverse Event Reporting System. Clin Infect Dis. 2015;60(5):777-80. 
[ADDRESS_878764], Cano M, Jankosky C. Postmarketing safety surveillance of trivalent 
recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System. Vaccine. 2017;35(42):5618-21. 
23 Seneviratne U. Guillain -Barré syndrome. Postgrad Med J. 2000;76(902):774-82. 
24 Salmon DA, Proschan M, Forshee R, et al. Association between Guillain- Barré syndrome 
and influenza A (H1N1) 2009 monovalent inactivated vaccines in the [LOCATION_003]: a meta- analysis. 
Lancet. 2013;381(9876):1461-8. 
[ADDRESS_878765] on Population Health and Public Health Practice: adverse effects of vaccines evidence of causality. Washington, D.C.: The National Academies Press; 2012. Availa ble at: 
https://www.nap.edu/read/[ZIP_CODE]/chapter/1. Accessed May 7, 2018. 
26 Leroy Z, Broder K, Menschik D, Shimabukuro T, Martin D. Febrile seizures after 2010-
2011 influenza vaccine in young children, [LOCATION_002]: a vaccine safety signal from the Vaccine Adverse Event Reporting System. Vaccine. 2012;30(11):2020-3. 
27 Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM; VSD Rapid Cycle Analysis Influenza Working Group. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine. 2012;30(11):2024-31. 
28 Duffy J, Weintraub E, Hambidge SJ, et al. Febrile seizure risk after vaccination in children 
6 to 23 months. Pediatrics. 2016;138(1):e20160320. 
29 Center for Disease Control and Prevention Website. Childhood Vaccines and Febrile 
Seizures. Available at: https://www.cdc.gov/vaccinesafety/concerns/febrile -seizures.html. 
Accessed May 7, 2018. 
[ADDRESS_878766] Dis. 2012;54(11):1608-14. 
 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 83 of 85
[COMPANY_011] Pasteur GRC90 
450–Fluzone® Quad, 529 –Flublok® Quad, 372 –Fluzone® HD 
Confidential/Proprietary Information  
Page 84 of 84 15 Signature [CONTACT_654783]/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.[ADDRESS_878767] Name
[CONTACT_29565]
-
-
-
Approver Name [CONTACT_1782]
(Universal Time)Reason for Signature
[CONTACT_125642] 24 May 2018
02:51:03I am approving this document
-
-
 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
              
GRC90
450–Fluzone® Quad, 529–Flublok® Quad, 372–Fluzone® HD
Protocol Version 1.0
Page 85 of 85
